Title of study : ED Influenza Therapeutic Pi[INVESTIGATOR_16116]: Oseltamivir vs. Peramivir 
NCT number: 02609399  
PI [CONTACT_2300]: Richard Rothman, MD, PhD  
Date of protocol : 09/26/16  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
1 
  
      
 
Influenza Therapeutic Pi[INVESTIGATOR_52081] 
A Pi[INVESTIGATOR_52082]: 15-001 
Version: 2.0 
 
 
Pharmaceutical Support Provided by:  [CONTACT_52138], Inc.  
IND Sponsor:  Andrea Dugas, MD, PhD  
Lead Co -Principal Investigators: Andrea Dugas, MD, PhD & Rich ard E. Rothman, 
MD, PhD  
IND #: 127482  
           
09/26/2016  
 
 
 
 
Influenz
a Therapeutic Pi[INVESTIGATOR_52083] 2.0 
 
 
 
IND Sponsor:                                           Richard E.  Rothman, MD, PHD  
Study Principle Investigator:     Richard E.  Rothman, MD, PHD  
Study Co -Investigators:     Andrea Dugas, MD, PHD  
                                                                      and Mustapha Saheed, MD  
 
 
Prepared by:  
 
[CONTACT_52139], PHD  
 
Westat  
[ADDRESS_55064]  
Rockville, MD [ZIP_CODE]  
 
5/18/2017  
 
 
 
 
  
 
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
1 
P a g e  1  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  2 6,  2 0 1 6  R E S E A R C H  P A R TI CI P A N T I N F O R M E D  C O N S E N T  A N D  P RI V A C Y  A U T H O RI Z A TI O N 
F O R M  
 
Pr ot o c ol  Titl e:   A  Pil ot  R a n d o mi z e d  C o ntr oll e d  Tri al f or  F e a si bilit y  of 
E nr olli n g  S u bj e ct s f or I nfl u e n z a  T h er a p e uti c  Tri al s  a n d 
A d mi ni st eri n g I nfl u e n z a  A nti vir al s i n t h e  E m er g e n c y 
D e p art m e nt t o  Hi g h  Ri s k  S u bj e ct s  
 
A p pli c ati o n  N o.:      I R B 0 0 0 8 0 4 0 5  
 
I N D S p o n s or:  A n dr e a  D u g a s,  M D,  P h D   
 
Pri n ci p al I n v e sti g at or:  A n dr e a  D u g as,  M D,  P h D  
D e p art m e nt  of  E m er g e n c y  M e di ci n e  
J o h ns  H o p ki ns  M e di c al I nstit uti o ns  5 8 0 1  S mit h  A v e n u e          
D a vis  B uil di n g,  S uit e  3 2 2 0  B alti m or e,  M D  2 1 2 0 9  
P h o n e:          4 1 0 -7 3 5 -6 4 0 0  
F a x:             4 1 0 -7 3 5 -6 4 2 5  
E m ail:          a d u g as 1 @j h mi. e d u      
 
  
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
2 
P a g e  2  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  [ADDRESS_55065] u d y:  
•  Y o u   ar e   b ei n g   a s k e d  t o  j oi n   a  r e s e ar c h   st u d y.   T hi s   c o n s e nt  f or m   e x pl ai n s  t h e  
r e s e ar c h  st u d y  a n d  y o ur  p art i n it.  Pl e a s e r e a d it  c ar ef ull y  a n d t a k e  a s  m u c h ti m e  a s y o u   n e e d.   A s k   y o ur   st u d y   d o ct or   or  t h e   st u d y  t e a m  t o   e x pl ai n   a n y   w or d s   or  
i nf or m ati o n t h at  y o u  d o  n ot  u n d er st a n d. 
•  Y o u  ar e  a  v ol u nt e er. If  y o u j oi n t h e  st u d y,  y o u  c a n  c h a n g e  y o ur  mi n d l at er.  T h er e  will b e  n o  p e n alt y  or l o s s  of  b e n efit s if  y o u  d e ci d e t o  q uit t h e  st u d y.   
•  D uri n g  t h e   st u d y,   w e   will  t ell   y o u  if   w e  l e ar n   a n y   n e w i nf or m ati o n  t h at   mi g ht   aff e ct w h et h er  y o u  wi s h t o  c o nti n u e t o  p a rti ci p at e. 
•  If  w e t hi n k  y o ur  p arti ci p ati o n i n t hi s  st u d y  m a y  aff e ct  y o ur  cli ni c al  c ar e, i nf or m ati o n 
a b o ut  y o ur  st u d y  p arti ci p ati o n  will  b e i n cl u d e d i n  y o ur  m e di c al r e c or d,  w hi c h i s  u s e d 
t hr o u g h o ut J o h ns  H o p ki ns.   D o ct or s  o ut si d e  of J o h ns  H o p ki ns m a y  n ot  h a v e  a c c e s s 
t o t hi s i nf or m ati o n.  Y o u  c a n  a s k t h e r e s e ar c h t e a m t o  s e n d t hi s i nf or m ati o n t o  a n y  of 
y o ur  d o ct or s.  
•  W h e n J o h ns  H o p ki ns   i s   u s e d  i n  t hi s   c o n s e nt  f or m,  it  i n cl u d e s  T h e J o h ns   H o p ki ns 
U ni v ersit y,   T h e  J o h ns   H o p ki ns   H os pit al,  J o h ns   H o p ki ns   B a y vi e w   M e di c al   C e nt er,  
H o w ar d  C o u nt y  G e n er al  H os pit al, J o h ns  H o p ki ns  C o m m u nit y  P h ysi ci a ns,  S u b ur b a n H os pit al,  Si bl e y  M e m ori al  H os pit al  a n d  All  C hil dr e n’s  H os pit al.
  
•  Bi o s p e ci m e n s   will   b e   c oll e ct e d  i n  t hi s   st u d y.   Bi o s p e ci m e n s   m a y i n cl u d e   a n y   of  t h e 
f oll o wi n g:   bl o o d,  ti ss u e,   s ali v a,   uri n e,   b o n e   m arr o w,   c ell s,   et c.   M o st   bi o s p e ci m e n s  
c o nt ai n  D N A,  w hi c h i s t h e  g e n eti c  c o d e f or  e a c h  p er s o n.  
•  A  d e s cri pti o n  of t hi s  cli ni c al tri al  will  b e  a v ail a bl e  o n  htt p:// w w w. Cli ni c al Tri al s. g o v,  a s 
r e q uir e d  b y U S  L a w.  T hi s  W e b  sit e  will  n ot i n cl u d e i nf or m ati o n t h at  c a n i d e ntif y  y o u. At  m o st, t h e  W e b  sit e  will i n cl u d e  a  s u m m ar y  of t h e r e s ult s.  Y o u  c a n  s e ar c h t hi s  W e b 
sit e  at  a n y ti m e.   
•  If  y o u  w o ul d li k e t o r e vi e w t h e i nf or m ati o n f or t hi s  st u d y,  or  a  s u m m ar y  of t h e r e s ult s, 
a s k t h e  st u d y t e a m  d o ct or f or t h e  Cli ni c al Tri al s. g o v  st u d y r e gi str ati o n  n u m b er.  
2.     Wh y i s t hi s r e s e ar c h  b ei n g  d o n e ?  
T hi s  r e s e ar c h  i s   b ei n g   d o n e  t o   e st a bli s h  t h e   u s e   of  t h e   e m er g e n c y   d e p art m e nt   a s   a  
pri m ar y  sit e f or  p arti ci p a nt  e nr oll m e nt i n r e s e ar c h  st u di e s t h at l o o k  at  dr u g s  u s e d  t o tr e at 
i nfl u e n z a  (“t h e  fl u”).   T hi s   will   h el p   u s   u n d er st a n d  t h e   b e st   w a y  t o   d e si g n   a n d   pl a n  r e s e ar c h  st u di e s t h at  will  u s e  st u d y  dr u g s t o tr e at  p ati e nt s  w h o  ar e  si c k  wit h t h e fl u.  
W e  will  b e  gi vi n g  o n e  of t w o  dr u g s  u s e d t o tr e at t h e fl u t o  e a c h  st u d y  p a rti ci p a nt,  eit h er 
o s elt a mi vir  or  p er a mi vir . B ot h  o s elt a mi vir  a n d  p er a mi vir  ar e  a p pr o v e d  b y t h e  F o o d  a n d 
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
3 
P a g e  3  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  [ADDRESS_55066] u g   A d mi ni str ati o n  ( F D A)   t o  tr e at  t h e  fl u  b ut  t h e   u s e   of   o s elt a mi vir   a n d   p er a mi vir  i n  
si c k er  i n di vi d u al s i s  n ot  a p pr o v e d  a n d i s  c o n si d er e d i n v e sti g ati o n al.  T h e  F D A i s  all o wi n g 
o s elt a mi vir  a n d  p er a mi vir t o  b e  u s e d i n t hi s  st u d y .  
P e o pl e  wit h  a  p o siti v e  fl u t e st fr o m t h eir  c urr e nt  e m er g e n c y  d e p art m e nt  vi sit  m a y j oi n. 
H o w  m a n y  p e o pl e  will  b e i n t hi s  st u d y ?  
U p t o  [ADDRESS_55067] u d y ?  
If  y o u  a gr e e t o  b e i n t hi s  st u d y,  w e  will  a s k  y o u t o  d o t h e f oll o wi n g t hi n g s: 
O n t h e  D a y  of  E nr oll m e nt:  S o m e   of  t h e s e  t e st s   a n d   pr o c e d ur e s   ar e  li k el y  t o   b e   p art   of  r e g ul ar   c ar e   a n d   m a y   b e  
d o n e  e v e n if it t ur n s  o ut t h at  y o u  d o  n ot t a k e  p art i n t h e r e s e ar c h  st u d y:  
•   A n s w er  q u e sti o n s  w hil e  y o u  ar e i n t h e  e m er g e n c y  d e p art m e nt  a b o ut  y o ur  c urr e nt 
s y m pt o m s,  a n y  m e di c ati o n s  y o u  m a y  b e t a ki n g,  a n d  y o ur  m e di c al  hi st or y.  W e  wi ll 
al s o  a s k f or  s o m e  b a si c i nf or m ati o n  a b o ut  y o u  s u c h  a s  y o ur  a g e,  s e x , r a c e,  a n d 
t el e p h o n e  n u m b er.  T hi s  will t a k e  a b o ut  [ADDRESS_55068] aff t o r e vi e w  y o ur  m e di c al r e c or d s  at  ot h er  h o s pit al s i n t h e f o ur  w e e k s 
aft er t o d a y’ s  vi sit t o t h e  e m er g e n c y  d e p art m e nt .  
•   H a v e  s o m e l a b or at or y t e st s, if t h e y  h a v e  n ot  b e e n  d o n e i n t h e l a st  [ADDRESS_55069] et e: 
o   Bl o o d:  w e  will  c oll e ct  [ADDRESS_55070] ( Bl o o d  or  Uri n e):  w e  will  c oll e ct  [ADDRESS_55071] s  will  b e  p art  of  y o ur  m e di c al r e c or d  a n d  pr o vi d e d t o  y o ur 
tr e ati n g  pr o vi d er.  
•   C h e st  x -r a y, if  o n e  w a s  n ot  d o n e  a s  p art  of  y o ur  m e di c al  c ar e i n t h e  e m er g e n c y 
d e p art m e nt.  
•   R e c ei v e  a  dr u g t o tr e at  y o ur fl u .  D e p e n di n g  o n  w hi c h  dr u g y o u  g et , t hi s m a y  t a k e 
u p t o  3 0  mi n ut e s.   
•   Y o u   will  b e  r a n d o ml y   a s si g n e d,   li k e  fli p pi n g   a   c oi n,  t o   o n e   of  t h e  t w o  fl u   dr u g s 
li st e d  b el o w:   
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
4 
P a g e  4  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  2 6,  2 0 1 6  o   O n e  gr o u p  will  r e c ei v e o s elt a mi vir ( T a mifl u)  b y  m o ut h , w hi c h  will t a k e  n o 
m or e t h a n  5  mi n ut e s . 
o   T h e  s e c o n d  gr o u p  will  r e c ei v e  p er a mi vir ( R a pi v a b)  t hr o u g h   a n I V,  w hi c h 
will t a k e  a b o ut  [ADDRESS_55072] et e.  
•   Bi o s p e ci m e n  c oll e cti o n fr o m  y o ur fl u t e st.  A n y l eft o v er  s p e ci m e n fr o m t h e  s w a b 
t h at  w a s t a k e n f or  y o ur fl u t e st  will  b e  st or e d  a n d  m a y  b e  u s e d f or f ut ur e t e sti n g. 
F or  1- 2  w e e k s  aft er  e nr oll m e nt :  
•   C o m pl et e  a  d ail y  di ar y f or  [ADDRESS_55073] a c e i n  p er s o n. It  will t a k e  a b o ut  1 0  mi n ut e s  e a c h 
d a y . 
•   C o nti n u e t o t a k e  a  dr u g t o tr e at  y o u r fl u, d e p e n di n g  o n  w hi c h  dr u g  y o u r e c ei v e . 
o   If  y o u  ar e t a ki n g  o s elt a mi vir,  y o u  will  b e  a s k e d t o t a k e t h e  dr u g  b y  m o ut h 
o n c e  or t wi c e  a  d a y f or  5  d a y s ( a t ot al  of  5 t o  1 0  d o s e s ).  T hi s  will t a k e l e s s 
t h a n  [ADDRESS_55074] u g  will  b e  pr o vi d e d t o  y o u fr e e  of  c h ar g e .  
•   St u d y  C h e c k -I n o n  d a y  [ADDRESS_55075] e  of  n a s al  s e cr eti o n s.  T hi s i s  a  bi o s p e ci m e n t h at  will  b e  s a v e d f or 
t e sti n g i n t h e f ut ur e t o l o o k  at t h e  a m o u nt  of fl u vir u s t h at  y o u  h a v e i n  y o ur 
b o d y.  
 
 
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
5 
P a g e  5  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  2 6,  2 0 1 6  O n  D a y  2 8 ( 4  w e e k s)  aft er  e nr oll m e nt  
•   A n s w er  s o m e  q u e sti o n s  a b o ut  h o w  y o u  h a v e  b e e n f e eli n g  a n d  a b o ut  a n y  ot h er 
d o ct or  or  h o s pit al  vi sit s  y o u  h a v e  h a d i n t h e ti m e  si n c e  y o u  st art e d t h e  st u d y.  T hi s 
will  t a k e   pl a c e   o v er  t h e   p h o n e   or,  if   y o u  r e m ai n  i n  t h e   h o s pit al,  t hi s   m a y  t a k e  
pl a c e i n  p er s o n. It  will t a k e  a b o ut  [ADDRESS_55076] u d y.  T hi s i s  w h at i s  c all e d  a n “i n ci d e nt al fi n di n g.”  
W e   will  l et   y o u   k n o w  if   w e   s e e   s u c h   a n  i n ci d e nt al  fi n di n g.   D e p e n di n g   o n  t h e  t y p e   of  
i n ci d e nt al fi n di n g,  w e   m a y  c o nt a ct   y o u   b y  m ail  or   b y  p h o n e.  I n t h e  c a s e   of   a   p ote nti al 
s eri o u s  e m er g e n c y,  s o m e o n e  m a y  g o t o  y o ur  h o m e.  
A  q u alifi e d  p er s o n ( u s u all y  a  m e m b er  of t h e r e s e ar c h t e a m)  will t al k t o  y o u if t h er e i s  a n 
i n ci d e nt al fi n di n g.  Y o u  d o  n ot  h a v e  a n  o pti o n t o  d e cli n e i nf or m ati o n  a b o ut  a n i n ci d e nt al 
fi n di n g. 
If  y o u  w a nt, w e  will  gi v e i nf or m ati o n  a b o ut t hi s i n ci d e nt al fi n di n g t o  y o ur  pri m ar y  d o ct or  or 
w e  will r ef er  y o u t o  a n  a p pr o pri at e  d o ct or f or f urt h er  e v al u ati o n.  
•   A n i n ci d e nt al fi n di n g  m a y  c a u s e  y o u t o f e el  a n xi o u s.   
•   Si n c e  a n i n ci d e nt al fi n di n g  will  b e  p art  of  y o ur  m e di c al r e c or d, it  m a y  aff e ct  y o ur 
c urr e nt  or f ut ur e lif e  or  h e alt h i n s ur a n c e  c o v er a g e.  T hi s ri s k  will  v ar y  d e p e n di n g o n t h e t y p e  of i n s ur a n c e  pl a n i n v ol v e d.   
T h e   c o st s  f or   a n y   c ar e  t h at   will   b e   n e e d e d  t o   di a g n o s e   or  tr e at   a n  i n ci d e nt al  fi n di n g  w o ul d  n ot  b e  p ai d f or  b y t hi s r e s e ar c h  st u d y.  T h e s e  c o st s  w o ul d  b e  y o ur r e s p o n si bilit y.  
R e q u e st t o  c oll e ct  a n d  st or e  bi o s p e ci m e n s f or f ut ur e r e s e ar c h   
A s  p art  of t hi s r e s e ar c h  st u d y,  w e  w o ul d li k e t o  a s k  y o u t o l et  u s  st or e  y o ur  bi o s p e ci m e n s 
a n d  h e alt h i nf or m ati o n f or f ut ur e r e s e ar c h.  T hi s r e s e ar c h  c o ul d i n cl u d e  ot h er  di s e a s e s.  
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
6 
P a g e  6  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  [ADDRESS_55077] e d  i n t h e S t u d y ? 
Will  y o u  all o w  u s t o  st or e t h e  bi o s p e ci m e n s  w e  c oll e ct f or t hi s  st u d y  f or  u s e i n f ut ur e r e s e ar c h?  Y o u  m a y  p arti ci p at e i n t hi s  st u d y  e v e n if  y o u  d o  n ot  all o w  u s t o  st or e  y o ur 
bi o s p e ci m e n s.  
Y
E S        _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _               
Si g n at ur e  of  P arti ci p a nt                 
NO          _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _        
Si g n a t ur e  of  P arti ci p a nt                
 
H o w l o n g  will  y o u  b e i n t h e  st u d y ?  
Y o u  will  b e i n t hi s  st u d y f or  2 8  d a y s ( 4  w e e k s  or  a b o ut  1  m o nt h) . 
4.   W h at  ar e t h e ri s k s  or  di s c o mf ort s  of t h e  st u d y ?  
 
Q u e sti o n s   
T h e  q u e sti o n s t h at  y o u  will  b e  a s k e d t o  c o m pl et e  d uri n g t h e  st u d y  m a y  c o nt ai n  q u e sti o n s t h at  c o ul d  b e  e m b arr a s si n g   a n d/ or  m a k e  y o u f e el  u n c o mf ort a bl e.  Y o u  m a y  g et tir e d  or 
b or e d   w h e n   w e   ar e   a s ki n g   y o u   q u e sti o n s   or   w h e n  y o u   ar e   c o m pl eti n g   q u e sti o n n air e s.  Y o u  d o  n ot  h a v e t o  a n s w er  a n y  q u e sti o n  y o u  d o  n ot  w a nt t o  a n s w er.   
  
Bl o o d  d r a w   
T o  dr a w  y o ur  bl o o d,  w e  will  pl a c e  a  s m all  n e e dl e i nt o  y o ur  v ei n  a n d  dr a w  1 t a bl e s p o o n  of 
bl o o d.  T hi s  c a n  b e  bri efl y  p ai nf ul,  a n d  c a n r e s ult i n  s o m e  br ui si n g  a n d/ or i nf e cti o n i n  t h at ar e a.    
T o  mi ni mi z e t h e s e ri s k s  a n d  di s c o mf ort s,  a tr ai n e d  p h y si ci a n,  n ur s e,  st u d y  c o or di n at or, 
or  d e si g n e e  will  c oll e ct t h e  s p e ci m e n s.  C ar e  will  b e t a k e n t o  o bt ai n t h e s e  s p e ci m e n s i n  a s af e  a n d  h y gi e ni c  m a n n er.  If  y o u  alr e a d y  h a v e  a n I V li n e  pl a c e d, w e  will  dr a w t h e  bl o o d fr o m t h e  e xi sti n g li n e if  p o s si bl e.    
Uri n e  c oll e cti o n   
If   y o u   ar e   a   w o m a n   of   c hil d b e ari n g   p ot e nti al   y o u   m a y  b e   a s k e d  t o   gi v e   u s   a   uri n e  
s p e ci m e n f or  a  pr e g n a n c y t e st, if  a  bl o o d  pr e g n a n c y  t e st i s  n ot  d o n e. T h er e  ar e  n o ri s k s or  di s c o mf ort s  a s s o ci at e d  wit h t hi s  pr o c e d ur e.   
 
 
 
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
7 
P a g e  7  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  [ADDRESS_55078] a c e d i n  y o ur  n o stril if  y o u  ar e i n  t h e h o s pit al  o n  D a y  3  a n d/ or  D a y  [ADDRESS_55079] u d y i s  0. 0 1 r e m ( a r e m i s  a  u nit of   a b s or b e d  r a di ati o n).   T hi s  i s  l e s s  t h a n  t h e   0. [ADDRESS_55080] s  (li k e   x -r a y s   or   C T   s c a n s)  i n   d e ci di n g   a b o ut  t h e  r a di ati o n  i n  t hi s  st u d y. If  y o u  h a v e  q u e sti o n s  a b o ut t h e t ot al  a m o u nt  of r a di ati o n  y o u  will  b e r e c ei vi n g,  y o u s h o ul d  a s k  y o ur  d o ct or.   
I nfl u e n z a d r u g s 
T hi s  i s   a  tr e at m e nt   st u d y.   O s elt a mi vir  ( T a mifl u)  i s  t h e   st a n d ar d   cli ni c al   c ar e  f or  t h e  
tr e at m e nt   of  i nfl u e n z a.  If   y o u  j oi n  t hi s   st u d y   y o u   m a y  r e c ei v e  t h at   dr u g   or   y o u   m a y  r e c ei v e  a n ot h er  dr u g,  p er a mi vir ( R a pi v a b), w hi c h i s  al s o  u s e d t o tr e at f or i nfl u e n z a.  T h e 
c h a n c e  of r e c ei vi n g t h e  st a n d ar d  of  c ar e  dr u g if  y o u j oi n t h e  st u d y  will  b e  d et er mi n e d  b y 
a  pr o c e s s  c all e d r a n d o mi z ati o n,  w hi c h i s li k e  a  c oi n fli p.   T h er e   ar e   s o m e   k n o w n   si d e   eff e ct s   of  t h e   st u d y   dr u g s,   o s elt a mi vir  ( T a mifl u)   a n d  p er a mi vir ( R a pi v a b) t h at  s o m e  p e o pl e  h a v e  e x p eri e n c e d,  a n d t h er e  m a y  b e  si d e  eff e ct s 
a n d  di s c o mf ort s t h at  ar e  n ot  y et  k n o w n.  B el o w  ar e  k n o w n  p o s si bl e  si d e  eff e ct s.  
 
•   O s elt a mi vir  
If   y o u  r e c ei v e  t hi s   dr u g   y o u   m a y   e x p eri e n c e   n a u s e a,   v o miti n g,   br o n c hiti s, 
i n s o m ni a  or  v erti g o. 
 It i s r ar e  b ut  s eri o u s if  y o u  e x p eri e n c e  s ki n/ h y p er s e n siti vit y r e a cti o n s ( a  s ki n r a s h) s u c h   a s   St e v e n s -J o h n s o n   S y n dr o m e,  t o xi c   e pi d er m al   n e cr ol y si s,   or   er yt h e m a  
m ultif or m e.   
 
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
8 
P a g e  8  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  2 6,  2 0 1 6  It  i s   al s o  r ar e   b ut   s eri o u s  if   y o u   e x p eri e n c e   a n y   n e ur o p s y c hi atri c   e v e nt s  ( e. g.,  
c o n f u si o n  or  a b n or m al  b e h a vi or).   
•   P er a mi vir  
I n s erti n g   a n  i ntr a v e n o u s  (I V)   c at h et er  t o   gi v e   y o u   p er a mi vir   m a y   c a u s e   p ai n,  br ui si n g,  s w elli n g  a n d  bl e e di n g  w h er e t h e  c at h et er i s  pl a c e d.  T h er e i s  al s o  a  ri s k of i nf e cti o n.    
If  y o u r e c ei v e t hi s  dr u g y o u  m a y  e x p eri e n c e  di arr h e a.  
 
It i s r ar e  b ut  s eri o u s if  y o u  e x p eri e n c e  s ki n/ h y p er s e n siti vit y r e a cti o n s ( a  s ki n r a s h) 
s u c h  a s  St e v e n s -J o h n s o n  S y n dr o m e  a n d  er yt h e m a  m ultif or m e.   
It  i s   al s o  r ar e   b ut   s eri o u s  if   y o u   e x p eri e n c e   a n y   n e ur o p s y c hi atri c   e v e nt s  ( e. g.,  
h all u ci n ati o n s,  d eliri u m,  or  a b n or m al  b e h a vi or).  
T h er e i s  al s o  a ri s k  of  d e at h fr o m i nfl u e n z a  
C o nfi d e nti alit y  
S u bj e ct   c o nfi d e nti alit y   will   b e   h el d   stri ctl y  i n  tr u st   b y  t h e   st u d y   d o ct or   a n d   st aff.   T hi s  
c o nfi d e nti alit y  will  b e  e xt e n d e d t o  c o v er t e sti n g  of  bi ol o gi c al  s p e ci m e n s i n  a d diti o n t o t h e 
cli ni c al i nf or m ati o n r el ati n g t o  s u bj e ct s.  
5.   Ar e t h er e ri s k s r el at e d t o  pr e g n a n c y ?  
Pr e g n a nt  w o m e n  c a n n ot t a k e  p art i n t hi s  st u d y. If  y o u  ar e  a  w o m a n  c a p a bl e  of  h a vi n g 
c hil dr e n,  y o u  m u st  h a v e  a  pr e g n a n c y t e st.  T h e  r e s ult s  of t h at t e st  m u st  b e  n e g ati v e f or y o u t o  c o nti n u e i n t h e  st u d y. If  y o u  b e c o m e  pr e g n a nt ( or  s u s p e ct  pr e g n a n c y)  b ef or e t h e 
st u d y i s  c o m pl et e d,  y o u  m u st i nf or m t h e  st u d y  d o ct or.  
6.   Ar e t h er e  b e n efit s t o  b ei n g i n t h e  st u d y ?  
T h er e  m a y  or  m a y  n ot  b e  a  dir e ct  b e n efit t o  y o u fr o m  b ei n g i n t h e  st u d y. If  y o u t a k e  p art 
i n t hi s  st u d y,  y o u  m a y al s o  h el p  ot h er s i n t h e f ut ur e.  
7.   W h at  ar e  y o ur  o pti o n s if  y o u  d o  n ot  w a nt t o  b e i n t h e  st u d y ?  
If  y o u  d e ci d e  n ot t o j oi n t hi s  st u d y,  ot h er  o pti o n s  ar e  a v ail a bl e.  Y o u  d o  n ot  h a ve t o j oi n t hi s  st u d y t o  g et tr e at m e nt.  Os elt a mi vir i s  a v ail a bl e f or  u s e  o ut si d e  of  t hi s r e s e ar c h  st u d y.  
Y o u  d o  n ot  h a v e t o j oi n t hi s  st u d y. If  y o u  d o  n ot j oi n,  y o ur  c ar e  at 
J o h ns  H o p ki ns  will  n ot 
b e  aff e ct e d.  
 
8.   Will it  c o st  y o u  a n yt hi n g t o  b e i n t hi s  st u d y ?   
Y o u  will r e c ei v e  a  s e p ar at e I n s ur a n c e  a n d  R e s e ar c h  P arti ci p a nt  Fi n a n ci al  R e s p o n si bilit y 
I nf or m ati o n  S h e et ( S h e et).  
T hi s  S h e et  will  gi v e  y o u t h e f oll o wi n g i nf or m ati o n:  
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
9 
P a g e  9  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  2 6,  2 0 1 6  •   T h e  pr o c e d ur e s, t e st s,  dr u g s  or  d e vi c e s t h at  ar e  p art  of t hi s r e s e ar c h  a n d t h at  will 
b e  p ai d f or  b y t h e  st u d y ( n o  c o st t o  y o u).   
 
•   T h e   pr o c e d ur e s,  t e st s,   dr u g s   or   d e vi c e s  t h at   will   b e   bill e d  t o   y o u   a n d/ or   y o ur  
h e alt h i n s ur er. If  y o u  h a v e  h e alt h i n s ur a n c e,  y o u  will  b e r e s p o n si bl e f or  a n y  c o -
p a y s  or  d e d u cti bl e s  n ot  c o v er e d  b y  y o ur i n s ur a n c e.   
 
9.   Will  y o u  b e  p ai d if  y o u j oi n t hi s  st u d y ?  
Y o u  will  b e  p ai d  u p t o $ [ADDRESS_55081] u d y: 
•   $ [ADDRESS_55082] eti o n  of  all  e nr oll m e nt  a cti viti e s . 
•   $ [ADDRESS_55083] 8  of t h e  1 4  d ail y  di ari e s . 
•   $ [ADDRESS_55084] u d y.   F e d er al t a x l a w r e q uir e s t h at  y o u  r e p ort  y o ur  r e s e ar c h  p a y m e nt s  w h e n   y o u 
fil e  y o ur t a x e s. If  y o ur t ot al  p a y m e nt s fr o m J o h ns  H o p ki ns  e x c e e d $ [ADDRESS_55085] u d y  e arl y ?  
•  Y o u  c a n  a gr e e t o  b e i n t h e  st u d y  n o w  a n d  c h a n g e  y o ur  mi n d l at er.  
•  If  y o u  wi s h t o  st o p,  pl e a s e t ell  u s ri g ht a w a y.  
•  L e a vi n g t hi s  st u d y  e arl y  will  n ot  st o p  y o u fr o m  g etti n g r e g ul ar  m e di c al  c ar e.   
If  y o u l e a v e t h e  st u d y  e arl y, J o h ns  H o p ki ns  m a y  u s e  or  gi v e  o ut  y o ur  h e alt h i nf or m ati o n 
t h at it  h a s  alr e a d y  c oll e ct e d if t h e i nf or m ati o n i s  n e e d e d f or t hi s  st u d y  or  a n y f oll o w-u p 
a cti viti e s .  
[ADDRESS_55086] u d y  e arl y ?   
Y o u  m a y  b e t a k e n  o ut  of t h e  st u d y if:  
•  St a yi n g i n t h e  st u d y  w o ul d  b e  h ar mf ul.  
•  Y o u  n e e d tr e at m e nt  n ot  all o w e d i n t h e  st u d y.  
•  Y o u f ail t o  f oll o w i n str u cti o n s. 
•  T h e  st u d y i s  c a n c ell e d.  
•  T h er e  m a y  b e  ot h er r e a s o n s t o t a k e  y o u  o ut  of t h e  st u d y t h at  w e  d o  n ot  k n o w  at 
t hi s ti m e.  
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
1 0 
P a g e  1 0  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  [ADDRESS_55087] e d ?   
W e  h a v e  r ul e s t o  pr ot e ct i nf or m ati o n  a b o ut  y o u.  F e d er al  a n d  st at e l a w s  an d t h e f e d er al 
m e di c al   Pri v a c y   R ul e   al s o   pr ot e ct   y o ur   pri v a c y.   B y   si g ni n g  t hi s  f or m   y o u   pr o vi d e   y o ur  
p er mi s si o n ,  c all e d   y o ur  “ a ut h ori z ati o n,”  f or  t h e   u s e   a n d   di s cl o s ur e   of  i nf or m ati o n  pr ot e ct e d  b y t h e  Pri v a c y  R ul e.  
T h e r e s e ar c h t e a m  w or ki n g  o n t h e  st u d y  will  c oll e ct i nf or m ati o n  a b o ut  y o u.  T hi s i n cl u d e s 
t hi n g s l e ar n e d fr o m t h e  pr o c e d ur e s  d e s cri b e d i n t hi s  c o n s e nt f or m.  T h e y  m a y  al s o  c oll e ct 
ot h er i nf or m ati o n i n cl u di n g  y o ur  n a m e,  a d dr e s s,  d at e  of  birt h,  a n d i nf or m ati o n fr o m  y o ur m e di c al  r e c or d s  ( w hi c h   m a y  i n cl u d e  i nf or m ati o n   a b o ut   HI V   st at u s ,  dr u g,   al c o h ol   or  s e x u all y  tr a n s mitt e d   di s e a s e  ( S T D)   tr e at m e nt,   g e n eti c  t e st  r e s ult s,   or   m e nt al   h e alt h  
tr e at m e nt). 
T h e r e s e ar c h t e a m  will  k n o w  y o ur i d e ntit y  a n d t h at  y o u  ar e i n t h e r e s e ar c h  st u d y.  O t h er 
p e o pl e   at  
J o h ns   H o p ki ns,   p arti c ul arl y   y o ur   d o ct or s,   m a y  al s o  s e e   or   gi v e   o ut   y o ur  
i nf or m ati o n. W e  m a k e t hi s i nf or m ati o n  a v ail a bl e t o  y o ur  d o ct or s f or  y o ur  s a f et y.   
P e o pl e   o ut si d e   of  J o h ns  H o p ki ns   m a y   n e e d  t o   s e e   or  r e c ei v e   y o ur  i nf or m ati o n  f or  t hi s 
st u d y.   E x a m pl e s  i n cl u d e   g o v er n m e nt   a g e n ci e s   ( s u c h   a s  t h e   F o o d   a n d   Dr u g  
A d mi ni str ati o n),  s af et y  m o nit or s,  ot h er  sit e s  i n t h e  st u d y  a n d  c o m p a ni e s t h at  s p o n s or t h e 
st u d y.   
If  y o u  ar e i n  a  c a n c er  st u d y t h at r e c ei v e s f e d er al f u n di n g, t h e  N ati o n al  C a n c er I n stit ut e 
( N CI)  n o w r e q uir e s t h at  w e r e p ort i d e ntifi a bl e i nf or m ati o n ( s u c h  a s,  zi p  c o d e)  a b o ut  y o ur p arti ci p ati o n.  Y o u  m a y  c o nt a ct t h e  N CI if  y o u  h a v e  q u e sti o n s  a b o ut  h o w t hi s i nf or m ati o n 
i s  u s e d.  
W e  c a n n ot  d o t hi s  st u d y  wit h o ut  y o ur  a ut h ori z ati o n  t o  u s e  a n d  gi v e  o ut  y o ur i nf or m ati o n. 
Y o u  d o  n ot  h a v e t o  gi v e  u s t hi s  a ut h ori z ati o n . If  y o u  d o  n ot, t h e n  y o u  m a y  n ot j oi n t hi s 
st u d y.  
W e   will   u s e   a n d   di s cl o s e   y o ur  i nf or m ati o n   o nl y   a s   d e s cri b e d  i n  t hi s  f or m   a n d  i n   o ur  
N oti c e   of   Pri v a c y   Pr a cti c e s;   h o w e v er,   p e o pl e   o ut si d e  
J o h ns   H o p ki ns   w h o  r e c ei v e   y o ur  
i nf or m ati o n m a y  n ot  b e  c o v er e d  b y t hi s  pr o mi s e  or  b y t h e f e d er al  Pri v a c y  R ul e .  W e tr y t o 
m a k e  s ur e t h at  e v er y o n e  w h o  n e e d s t o  s e e  y o ur i nf or m ati o n  k e e p s it  c o nfi d e nti al  –  b ut w e  c a n n ot  g u ar a nt e e t h at  y o ur i nf or m ati o n  will  n ot  b e r e -di s cl o s e d . 
T h e  u s e  a n d  di s cl o s ur e  of  y o ur i nf or m ati o n  h a s  n o ti m e li mit.  Y o u  m a y r e v o k e ( c a n c el ) 
y o ur   p er mi s si o n  t o   u s e   a n d   di s cl o s e   y o ur  i nf or m ati o n   at   a n y  ti m e   b y   n otif yi n g  t h e  
Pri n ci p al  I n v e sti g at or   of  t hi s   st u d y   b y   p h o n e   or  i n   writi n g.  If   y o u   c o nt a ct  t h e   Pri n ci p al  I n v e sti g at or  b y  p h o n e, y o u  m u st f oll o w -u p  wit h  a  writt e n r e q u e st t h at i n cl u d e s t h e  st u d y 
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
1 1 
P a g e  1 1  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  [ADDRESS_55088] i nf or m ati o n.  T h e  Pri n ci p al I n v e sti g at or’ s  n a m e,  a d dr e s s,  p h o n e 
a n d f a x i nf or m ati o n  ar e  o n  p a g e  o n e  of t hi s  c o n s e nt f or m.   
If  y o u  d o c a n c el  y o ur  a ut h ori z ati o n  t o  u s e  a n d  di s cl o s e  y o ur i nf or m ati o n,  y o ur  p art i n t hi s 
st u d y   will   e n d   a n d   n o  f urt h er  i nf or m ati o n   a b o ut   y o u   will   b e   c oll e ct e d.   Y o ur   r e v o c ati o n 
(c a n c ell ati o n )  w o ul d  n ot  aff e ct i nf or m ati o n  alr e a d y  c oll e ct e d i n t h e  st u d y ,  or i nf or m ati o n 
w e  di s cl o s e d  b ef or e  y o u  wr ot e t o t h e  P ri n ci p al I n v e sti g at or t o c a n c el  y o ur  a ut h ori z ati o n . 
[ADDRESS_55089] u d y ?   
J o h ns  H o p ki ns  a n d t h e f e d er al  g o v er n m e nt  d o  n ot  h a v e  a  pr o gr a m t o  p a y  y o u if  y o u  ar e 
h urt  or  h a v e  ot h er  b a d r e s ult s fr o m  b ei n g i n t h e  st u d y.  H o w e v er,  m e di c al  c ar e  at J o h ns 
H o p ki ns  i s  o p e n t o  y o u  a s it i s t o  all  si c k  or i nj ur e d  p e o pl e. 
T h e  c o st s f or  a n y tr e at m e nt  or  h o s pit al  c ar e  y o u r e c ei v e  a s t h e r e s ult  of  a  st u d y -r el at e d 
i nj ur y t h at  ar e  n ot  c o v er e d  b y  a  h e alt h i n s ur er  will  b e  bill e d t o  y o u. 
B y  si g ni n g t hi s f or m  y o u  will  n ot  gi v e  u p  a n y ri g ht s  y o u  h a v e t o  s e e k  c o m p e n s ati o n f or 
i nj ur y.  
[ADDRESS_55090] u d y ?  
a.   W h at i s t h e I n stit uti o n al  R e vi e w  B o ar d (I R B)  a n d  h o w  d o e s it  pr ot e ct  y o u ?   
T h e J o h ns  H o p ki ns  M e di ci n e I R B i s  m a d e  u p  of:  
•  D o ct or s ; 
•  N ur s e s ; 
•  Et hi ci st s ; 
•  N o n - s ci e nti st s; a n d  
•  P e o pl e  fr o m t h e l o c al  c o m m u nit y  
 
T h e  I R B  r e vi e w s   h u m a n  r e s e ar c h   st u di e s.  It   pr ot e ct s  t h e  ri g ht s   a n d   w elf ar e   of  t h e  p e o pl e t a ki n g  p art i n t h o s e  st u di e s.  Y o u  m a y  c o nt a ct t h e I R B if  y o u  h a v e  q u e sti o n s 
a b o ut  y o ur ri g ht s  a s  a  p arti ci p a nt  or if  y o u t hi n k  y o u  h a v e  n ot  b e e n tr e at e d f airl y.  T h e 
I R B   offi c e   n u m b er  i s  
[ADDRESS_55091] u d y  at  a n ot h er  sit e, t h at 
sit e  (i n stit uti o n)  i s   s ol el y  r e s p o n si bl e  f or  t h e   s af e   c o n d u ct   of  t h e   st u d y   a n d  f or  
f oll o wi n g t h e  pr ot o c ol  a p pr o v e d  b y t h e J o h ns  H o p ki ns  I R B.  
 
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
1 2 
P a g e  1 2  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  [ADDRESS_55092] u d y ?   
C all  t h e   pri n ci p al  i n v e sti g at or,  Dr.  A n dr e a  D u g as   at [ADDRESS_55093] u d y ?   
If   y o u  t hi n k   y o u   ar e  i nj ur e d   or  ill   b e c a u s e   of  t hi s   st u d y,   c all  Dr.  D u g as  at  [ADDRESS_55094] u d y ?  
J o h ns  H o p ki ns  a n d  o ur r e s e ar c h  p art n er s  w or k t o  u n d er st a n d  a n d  c ur e  di s e a s e s.  T h e 
bi o s p e ci m e n s  a n d/ or  d at a  y o u  pr o vi d e  ar e i m p ort a nt t o t hi s  eff ort.  
 If  y o u j oi n t hi s  st u d y,  y o u  s h o ul d  u n d er st a n d t h at  y o u will  n ot  o w n  y o ur  bi o s p e ci m e n s or  d at a,  a n d  s h o ul d r e s e ar c h er s  u s e t h e m t o  cr e at e  a  n e w  pr o d u ct  or i d e a,  y o u  will n ot  b e n efit fi n a n ci all y.   
 
Wit h   a p pr o pri at e   pr ot e cti o n s  f or   pri v a c y,  
J o h ns    H o p ki ns   m a y   s h ar e   y o ur  
bi o s p e ci m e n s  a n d i nf or m ati o n  wit h  o ur r e s e ar c h  s p o n s or s  a n d  p art n er s.  Y o ur  n a m e 
or  a n y  ot h er i d e ntif yi n g i nf or m ati o n  will  n ot  b e i n cl u d e d.  
1 5.   W h at  d o e s  y o ur  si g n at ur e  o n t hi s  c o n s e nt f or m  m e a n ?   
  Y o ur  si g n at ur e  o n t hi s f or m  m e a n s t h at:  
•  Y o u  u n d er st a n d t h e i nf or m ati o n  gi v e n t o  y o u i n t hi s f or m .  
•  Y o u  a c c e pt t h e  pr o vi si o n s i n t h e f or m . 
•  Y o u  a gr e e t o j oi n t h e  st u d y .  
•  Y o u   will   n ot   gi v e   u p   a n y  l e g al  ri g ht s   b y   si g ni n g  t hi s   c o n s e nt  f or m.   
 
 
 
 
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
1 3 
P a g e  1 3  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  2 6,  2 0 1 6  W E  WI L L  GI V E  Y O U  A  C O P Y  O F  T HI S  SI G N E D  A N D  D A T E D  C O N S E N T  F O R M  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Si g n at ur e  of  P arti ci p a nt                                 ( Pri nt  N a m e)                                            D at e/ Ti m e   
 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Si g n at ur e  of  P er s o n  O bt ai ni n g  C o n s e nt        ( Pri nt  N a m e)                                            D at e/ Ti m e  
 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Si g n at ur e  of  Wit n e s s t o  C o n s e nt                     ( Pri nt  N a m e)                                      D at e/ Ti m e   
Pr o c e d ur e s  ( o pti o n al  u nl e s s I R B  
or  s p o n s or  r e q uir e d) 
 
N O T E : A  C O P Y  O F  T H E  SI G N E D,  D A T E D  C O N S E N T  F O R M  M U S T  B E  K E P T  B Y  T H E  P RI N CI P A L I N V E S TI G A T O R;  A  C O P Y  M U S T  B E  GI V E N  T O  T H E 
P A R TI CI P A N T; I F  Y O U  A R E  U SI N G  E PI C  F O R  T HI S  S T U D Y  A  C O P Y  M U S T  B E  F A X E D  T O  4 1 0 -3 6 7 -7 3 8 2; I F  Y O U  A R E  N O T  U SI N G  E PI C  A  C O P Y 
M U S T  B E  P L A C E D I N  T H E  P A R TI CI P A N T’ S  M E DI C A L  R E C O R D ( U N L E S S  N O  M E DI C A L  R E C O R D  E XI S T S  O R  WI L L  B E  C R E A T E D).   
 
O N L Y  C O N S E N T  F O R M S  T H A T I N C L U D E  T H E J O H N S  H O P KI N S  M E DI CI N E  L O G O  C A N  B E  U S E D  T O  O B T AI N  T H E  C O N S E N T  O F  R E S E A R C H 
P A R TI CI P A N T S.  
 
  
D o  n ot  us e t his f or m f or  c o ns e nti n g r es e ar c h  
p arti ci p a nts  u nl ess t h e J o h ns  H o p ki ns  M e di ci n e  L o g o  a p p e ar s  h er e.  D at e:  S e pt e m b er  2 6,  2 0 1 6  Pri n ci p al I n v esti g at or:  A n dr e a  D u g as,  M D,  P h D  A p pli c ati o n  N o.:  I R B 0 0 0 8 0 4 0 5 
 
1 4 
P a g e  1 4  of  1 4  
C o m bi n e d I nf or m e d  C o ns e nt/ A ut h ori z ati o n  S e pt e m b er  [ADDRESS_55095] u d y.  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Si g n at ur e  of  I n v e sti g at or                        ( Pri nt  N a m e)                                                     D at e/ Ti m e 
 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Si g n at ur e  of  P arti ci p a nt                          ( Pri nt  N a m e)                                                     D at e/ Ti m e   
 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Si g n at ur e  of  Wit n e s s t o  C o n s e nt                     ( Pri nt  N a m e)                                            D at e/ Ti m e   
Pr o c e d ur e s  ( o pti o n al  u nl e s s I R B  
or  s p o n s or  r e q uir e d) 
 
 
 
  
N O T E : A  C O P Y  O F  T H E  SI G N E D,  D A T E D  C O N S E N T  F O R M  M U S T  B E  K E P T  B Y  T H E  P RI N CI P A L I N V E S TI G A T O R;  A  C O P Y  M U S T  B E  GI V E N  T O  T H E 
P A R TI CI P A N T; I F  Y O U  A R E  U SI N G  E PI C  F O R  T HI S  S T U D Y  A  C O P Y  M U S T  B E  F A X E D  T O  4 1 0 -3 6 7 -7 3 8 2; I F  Y O U  A R E  N O T  U SI N G  E PI C  A  C O P Y 
M U S T  B E  P L A C E D I N  T H E  P A R TI CI P A N T’ S  M E DI C A L  R E C O R D ( U N L E S S  N O  M E DI C A L  R E C O R D  E XI S T S  O R  WI L L  B E  C R E A T E D).   
 
 
O N L Y  C O N S E N T  F O R M S  T H A T I N C L U D E  T H E J O H N S  H O P KI N S  M E DI CI N E  L O G O  C A N  B E  U S E D  T O  O B T AI N  T H E  C O N S E N T  O F  R E S E A R C H 
P A R TI CI P A N T S.  
 
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/[ADDRESS_55096] Identification  .................................................  5 
1.4.2  Randomization  ...........................................................  6 
1.4.3  Blinding/Unblinding  ..................................................  [ADDRESS_55097] Status  ......................................  16 
Table 4. Summary of FLU -PRO Symptoms ..........................  17 
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
3 
 Table 5. Clinical Outcomes ....................................................  18 
Table 6. Influenza -Related Complications  ............................  20 
Table 7. Characteristics of Subjects Initially Admitted 
to the Hospi[INVESTIGATOR_52084]  .....................................  21 
Table 8. Patient Screening and Testing for Influenza  ............  22 
Table 9. Summary of Adverse Events by [CONTACT_52140], with number (%) of 
subjects reporting at least one adverse event ...........  23 
Table 10. Summary of Adverse Events by [CONTACT_52141]  .....................................  23 
Table 11. Frequency of Protocol -Specific Adverse 
Event  ........................................................................  24 
4.2 Mock Graphs  ..........................................................................  25 
Figure 1. Study Patient Screening and Enrollment  ................  25 
Figure 2. FLU -PRO Symptom Severity Score for 
Enrolled Patients, by [CONTACT_52142], 
up to 14 Days from Enrollment  ...............................  26 
Figure 3. Karnofsky Performance Scale, Mean and 95% 
Confidence Band of Daily Scores  ...........................  26 
Figure 4. Severity of Disease for Hospi[INVESTIGATOR_34297], 
up to 14 Days from Enrollment  ...............................  26 
Figure 5. Ordinal Scale for Hospi[INVESTIGATOR_34297], up to 
14 Days from Enrollment  ........................................  26 
4.3 Mock Listings  ........................................................................  27 
Listing 1. Patient Level Adverse Events  ................................  27 
Listing 2. Serious Adverse Events  .........................................  28 
Listing 3. Deaths  ....................................................................  28 
 
 
  
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/[ADDRESS_55098]  Design  
This pi[INVESTIGATOR_52085] -label randomized controlled clinical trial. It is designed to 
demonstrate the feasibility of utilizing emergency departments (ED) as a primary site for subject 
enrollment in clinical trials evaluating influenza therapeutics, providing pi[INVESTIGATOR_52086]. Adults presen ting to the ED with laboratory -confirmed 
influenza who meet Centers for Disease Control and Prevention (CDC) criteria for antiviral 
treatment will be enrolled. Subjects will be randomized to either oral (oseltamivir) or intravenous 
(IV) (peramivir) antivir al treatment.  
 
1.2 Objectives  
1.2.1 Efficacy  
[IP_ADDRESS]  Primary Objective  
To prospectively enroll high -risk subjects with laboratory -confirmed influenza into a 
randomized, open -label study of oral versus IV influenza therapeutic to include symptom 
evaluation and outcome assessments. 
 
[IP_ADDRESS]  Secondary Objectives  
Secondary Objective 1: To identify influenza -positive patients utilizing a previously 
established triage -based assessment and rapid testing algorithm for suspected influenza 
infection.  
 
Secondary Objective 2: To retrospec tively evaluate all potentially eligible patients for 
potential enrollment biases.  
 
Secondary Objective 3: To create a repository of residual nasopharyngeal (NP) samples 
collected from ED patients with suspected influenza illness.   
 
1.2.2 Safety  
The safety will be assessed by [CONTACT_52143] (AEs) and all serious adverse events (SAEs). The overall occurrences of 
AEs and SAEs will be reported by [CONTACT_1196] (SOC) and Preferr ed Term (PT). The 
AEs and SAEs will also be evaluated and reported by [CONTACT_52144], severity 
and the outcome. All the results will be summarized by [CONTACT_52145]/or by [CONTACT_52146].  
 
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
5 
 1.2.3 Pharmacokinetics  
The pharmacokinetics of influenza antivirals will not be studied.                                                  
1.3 Treatment s  
All eligible subjects will be randomized to receive one of two treatment groups . They will receive 
either oral or IV antiviral treatment.  
 
1.3.1  Treatment Assignment  
Randomization will be carried out using a computerized randomization system in the ratio of 
1:1. It will be performed by [CONTACT_52147], laboratory results and 
verification of all eligibility criteria have been performed.  
 
Subjects randomized to the oral treatment arm will receive oral oseltamivir. Subjects 
randomized to the IV treatment group will receive IV peramivir.  
 
1.3.2  Selection and Timing of Doses  
Influenza antivirals will be dosed based on creatinine clearance (CrCl) results, as described 
below. CrCl will be calculated using the Cockcroft Gault equation (see Manual of Operating 
Procedures (MOP)) . 
 
Treat
ment  CrCl Res
ult Dosag
e Frequ
ency/Duration  
Oral 
Oselt
amivir  >60 mL/min  75 mg  Twice daily (every 12 hours) for 5 days  
>30 – 
60 mL/min  30 mg  Twice daily (every 12 hours) for 5 days  
>10 – 
30 mL/min  30 mg  Once daily (every 24 hours) for 5 days  
IV 
Pera
mivir  ≥50 mL/min 600 mg  One time  
30 – 49 mL/m
in 200 mg  One time  
10 – 29 mL/m
in [ADDRESS_55099] during their current ED visit. If a patient appears to be 
eligible, research staff will  approach the patient, verify that the patient meets eligibility criteria, 
and determine if he/she would like to participate in the study.  
 
 
 
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/[ADDRESS_55100]  
not meet any of the  exclusion  criteria listed in the protocol at the time of screening. Screening 
and enrollment occur at the same visit. Screened patients who are eligible and provide written 
consent to participate in the study, will be randomized to a treatment arm and c onsidered as 
enrolled in the study.  
 
For secondary objective 2, research staff will identify subjects by [CONTACT_52148].  (See Protocol).  
 
For all eligible patients, research staff will review the ED and hospi[INVESTIGATOR_52087] a set of structured clinical data forms to collect the following: basic 
demographic data; symptoms rel ated to the Clinical Decision Guideline (CDG ); criteria for 
CDC antiviral treatment; initial presentation and clinical course at the ED, including antiviral 
treatment, antibiotic treatment, Xpert Flu test or other influenza test information; and hospi[INVESTIGATOR_52088]. 
 
1.4.2  Randomization  
Subjects will be randomized to receive one of two treatment groups using a computerized 
randomization system in the ratio of 1:1. Randomization will be performed at study level and 
not stratified by [CONTACT_3725]. 
 
1.4.3  Blinding/Unblinding  
This is an open- label study, and the administration of treatments will not be blinded.   
 
1.4.[ADDRESS_55101] to follow up or 
cannot be evaluated . 
 
1.4.5  Data Monitoring  
Data and safety will be monitored by [CONTACT_28749] (SMC), consisting of 
the IND sponsor, JHH Co -PIs, JHU Research Program Manager, Biomedical Advanced 
Research and Development Authority  (BARDA ) Medical Officer, Independent Safety Monitor 
(ISM), and study biostatistician  (See Data and Safety Monitoring Plan (DSMP)) . 
  
  
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/[ADDRESS_55102] 50 subjects per site, per influenza season. This sample size 
was determined, in collaboration with the Office of the Assistant Secretary for Preparedness and 
Response ( ASPR )/BARDA, to be adequate for this pi[INVESTIGATOR_52089] w hich is being conducted 
specifically to examine the feasibility of achieving higher recruitment rates than has historically 
been achieved in other clinical venues, and the ability to reliably collect useful therapeutic endpoint 
data from an ED enrollment s ite. Estimates are based on data from the JHH ED 2014 -2015 
influenza season using the CDG testing algorithm, where 1604 patients were tested for influenza 
between November 2014 and April 2015, and 311 influenza -positive patients were identified. Of 
those 3 11 patients, approximately 75% met CDC criteria for influenza treatment (i.e., potential 
enrollment in the study) and 40% were admitted to the hospi[INVESTIGATOR_307]. As [ADDRESS_55103] approximately 25% 
fewer influenza -positive patients. Based on similar previous ED based therapeutic clinical trials 
conducted at the JHH ED, it is anticipated that 56% of eligible patients will agree to participate in 
the study. Therefore, assuming a routi ne influenza season, there will be an estimated 174 eligible 
patients, of whom 97 will be enrolled (58 discharged, 39 admitted). Based on these estimates, at 
least 50 (conservatively) and up to 225 subjects could be enrolled and followed for 28 days.  
 
2.2 Analysis Population  
The analysis population includes adults presenting to the ED with laboratory -confirmed influenza 
who meet CDC criteria for antiviral treatment . Detailed inclusion/ exclusion criteria are listed in 
the Protocol.  
 
2.3 Data Handling 
2.3.1 Outcome Measures and Predictors  
 
Outcomes : 
 
a. For t
he Primary Objective:   
 
- The number of subjects successfully enrolled  
- The proportion of subjects who received  treatment with IV  study drug in the  ED 
- The proportion of subjects who received (first dose) oral study drug in the ED 
- The proportion of subjects who complete follow -up.  
In addition, the following clinical measures will be evaluated for planning future clinical trial 
endpoints:  
 
· For all study subjects: 
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
8 
 - Reported symptoms (including FLU -PRO Symptom Ques tionnaire)  
- Daily functional assessment  
- Patient Global Impression of Change (PGIC) on Day 7 and Day 28  
- Patient Global Impression of Severity (PGIS) at enrollment, and on Day 7 and Day 28  
- Number of subsequent medical visits or hospi[INVESTIGATOR_52090] 28 days  of enrollment 
- Influenza -related complications including pneumonia, myocardial infarction, and 
stroke. 
 
· For subjects initially admitted to the hospi[INVESTIGATOR_52084]:  
- Severity of disease based on Intensive Care Unit (ICU) admission, mechanical 
ventilation, or oxygen supplementation  
- Ordinal scale up to 14 days:  
§ Death  
§ Receiving mechanical ventilation or extracorporeal membrane oxygenation 
(ECMO)  
§ In ICU (without mechanica l ventilation or ECMO)  
§ Non-ICU hospi[INVESTIGATOR_059], requiring supplemental oxygen  
§ Non-ICU hospi[INVESTIGATOR_059], not requiring supplemental oxygen  
§ Not hospi[INVESTIGATOR_057], but unable to resume normal activities  
§ Not hospi[INVESTIGATOR_52091].  
 
b. For the Secondary Objective 1:  
 
- The proportion of ED patients who were screened for influenza  
- The proportion of screened patients who met testing criteria  
- The proportion of patients who met testing criteria who were tested for influenza  
- The proportion of patients tested for influenza who were positive for influenza.  
 
c. For the Secondary Objective 2:  
 
- The proportion of eligible patients who were enrolled  
- Comparison of d emographic characteristics between those who were enrolled in the study 
versus those who w ere identified to be potentially eligible through the retrospective chart 
review.  
§ Age 
§ Sex 
§ Race  
§ Ethnicity  
 
d. For the Secondary Objective 3:  
 
- The creation of a robust repository using all remnant samples of patients tested using the 
triage -based assessment and testing algorithm from November through April 2015 - 2017. 
Note that this is not a qua ntitative outcome.  
 
Potential p redictors  (independent variables)  of interest : 
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
9 
  
· Enrollment : We will compare demographic characteristics between those who were 
enrolled and randomized in the study versus those who were eligible but not enrolled 
(declined, screen failure etc.).  
· Influenza Type: We w ill compare study outcomes between subjects with Influenza A and 
B. 
· Other clinical characteristics: We will compare study outcomes by [CONTACT_52149], historical (i.e. past medical history and co -morbidities), and clinical 
characteristics.  
· Study site:  There are [ADDRESS_55104] missing information, we will further explore  the 
pattern of missing d ata, and assess whether missingness or loss to follow up is associated with 
subjects’ characteristics, disease severity or any other factors.  
 
2.[ADDRESS_55105] deviation, range for continuous 
outcomes and frequency/proportion for categorical outcomes will be used to characterize study 
outcomes. 
 
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
10 
 In addition, we will compare demographic char acteristics between those who were enrolled 
and randomized in the study versus those who were eligible but not enrolled (declined, screen 
failure , etc.).  
 
2.4.[ADDRESS_55106] characteristics and the primary out comes by 
[CONTACT_3725].  
 
  
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/[ADDRESS_55107] characteristics will be presented (see Table s 1 and 2). These characteristics will be 
summarized separately by [CONTACT_52150].  
 
3.2 Analysis of Primary Objectives  
Primary Objective:  To prospectively enroll high -risk subjects with laboratory -confirmed 
influe
nza into a randomized, open -label study of oral versus IV influenza therapeutic to include 
symptom evaluation and outcome assessments.  
 
Analysis:  Number of patients screened, enrolled and randomized will be plotted in Figure 1. 
Descriptive statistics including mean, median, standard deviation, range for continuous outcomes 
and frequency/proportion for categorical outcomes will be used to characterize study outcomes.  
 
All results will be summarized separately by [CONTACT_52150]. Results will be 
summarized in Tables 3-7. Ordinal scale up to 14 days for subjects who initially admitted to the 
hospi[INVESTIGATOR_52092] t, as well as Karnofsky Performance Scale will also be 
plotted (Figures 2 and 3).  
 
3.3 Analysis of Secondary Objectives  
Secondary Objective 1 : To identify influenza -positive patients utilizing a previously established 
triage -ba
sed assessment and rapid test ing algorithm for suspected influenza infection.  
 
Analysis:  Frequencies and proportions will be presented in Table 8 . 
 
Secondary Objective 2 : To retrospectively evaluate all potentially eligible patients for potential 
enroll
ment biases.   
 
Analysis:  The analysis will involve a retrospective chart review and comparisons of subject 
characteristics. It is not part of Westat’s scope of work, and is therefore not included in this SAP.  
 
Secondary Objective 3 : To create a repository of residual nasopharynge al (NP) samples collected 
from E
D patients with suspected influenza illness.  
 
Analysis:  There is no quantitative data collection for this objective. No statistical analysis will 
be performed.  
 
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
12 
 3.4 Analysis of Efficacy and  Safety  
3.4.1  Efficacy  
As this is an exploratory study, data analysis will be principally descriptive. Potential clinical 
endpoints will be described using descriptive statistics for the purposes of future trial 
planning, and no statistical comparisons between the oral and IV antiviral arms will be made.  
 
3.4.2  Safety  
Safety will be assessed by [CONTACT_52151]. The overall occurrences of AEs and SAEs will be 
reported by [CONTACT_3592]. The AEs and SAEs will also be evaluated and rep orted by [CONTACT_52152], severity and the outcome. All the results will be summarized by 
[CONTACT_52145]/or by [CONTACT_52153]. Resu lts will be presented in Tables 9 - 11 and 
Listings 1 – 3.  
 
 
  
4. PROPOSE
D SUMMARY TABLES, GRAPHS AND LISTINGS  
4.[ADDRESS_55108]  Demographics  
Chara
cteristics  Site 
1 Site 
2 Total  
 Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  
Age    
      
        n          
 Mean 
(SD), Min --Max           
Sex, 
n (%)           
 Femal
e          
 Male     
      
Ethnici
ty, n (%)           
 Hispa
nic or Latino           
 Non-Hisp
anic or Non -Latino           
 Unkno
wn          
Race,
 n (%)          
 Ameri
can Indian or Alaskan Native           
 Asian   
        
 Black
 or African American           
 Nativ
e Hawaiian/Other Pacific  Islander           
 White   
        
 Other   
        
CDC Cri
teria for Antiviral Treatment, n (%)           
 Hospi
[INVESTIGATOR_52093]/P neumonia           
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
14 
 Chara
cteristics  Site 
1 Site 
2 Total  
 Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  
 Age 6
5 or Greater           
 Chron
ic Pulmonary           
 Chron
ic Cardiovascular           
 Chron
ic Renal           
 Chron
ic Hepatic           
 Chron
ic Hematologic           
 Chron
ic Metabolic           
 Chron
ic Neurologic           
 Immun
osuppression           
 Pregn
ancy  or Less than Two Weeks Postpartum           
 Morbid
 Obesity           
 Resid
es in N ursing Home          
 Nativ
e American           
 
Study
 Arm :   
Arm 1 = O
ral antiviral treatment (Oseltamivir)   
Arm 2 = IV antiviral treatment (Peramivir)  
 
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/[ADDRESS_55109]  Symptom Onset and Baseline NEWS Score  
 
N (%)  Site 
1 Site 
2 Total  Influ
enza Type  
Arm 1
 
(n= )  Arm 2
 
(n= ) Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  A 
(n= )  B 
(n= )  
Time of
 Symptom Onset 
at Enrollment             
 Withi
n 2 Days             
 3 Days             
 4 Days             
NEW S Sc
ore            
 Median
 (Min —Max)             
 0            
 1-3            
 4-6            
 >6            
  
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/[ADDRESS_55110]  Status  
 
 
N (%)  Site 
1 Site 
2 Total  Influ
enza Type  
Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  A 
(n= )  B 
(n= )  
Subje
cts Enrolled             
Subje
cts Completed 
Treatment (%) in the ED             
Subje
cts Completed 
Follow up             
Numbe
r of Doses (Median,  
Min—Max)   - -  - -  - - - - 
NEW S Sc
ore            
Perce
nt Daily Dairies 
Completed             
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
17 
 Table 4 . Summary of FLU -PRO Symptoms  
 
 
Sympt
om Severity 
Score
 by [CONTACT_52154]  (S
tandard Deviation),  Min -Max 
Site 
1 Site 
2  Total  Influ
enza Type  
Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  A 
(n= )  B 
(n= )  
Nose             
Throat             
Eyes             
Chest
/ Respi[INVESTIGATOR_52094]/
 Systemic             
Total    
         
# Days M
issed 
Questionnaire             
 
 
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
18 
 Table 5 . Clinical Outcomes  
 
Outco
mes Site 
1 Site 
2 Total  Influ
enza 
Type  
Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  A 
(n= )  B 
(n= )  
Pneumo
nia             
 Inpat
ient, n (%)            
 Outpa
tient, n (%)             
 Pneumo
nia Severity Index  
 (Median,  Min—Max)             
Hospi
[INVESTIGATOR_059] , n (%)             
 LOS  
 (Mean,
 St. Dev.,  Min—Max)             
 Hospi
[INVESTIGATOR_52095] ,   n (%)   
 LOS  
 (Mean, St. Dev.,  Min—Max)             
Karno
fsky Performance Scale             
 Mean,
 St. Dev.             
 Median
, Min —Max            
Patie
nt Global Impression of Change 
 (Median, Min —Max)             
 Day 7   
          
 Day 2
8            
Patie
nt Global Impression of 
Severity  (Median, Min —Max)             
 Enrollm
ent            
 Day 7   
          
 Day 2
8            
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
19 
 Outco
mes Site 
1 Site 
2 Total  Influ
enza 
Type  
Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total 
(n= )  A 
(n= )  B 
(n= )  
Numbe
r of Subsequent Medical 
Visits or Hospi[INVESTIGATOR_602]  
 (Median, Min —Max)             
 
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
20 
 Table 6. Influenza -Related Complications  
 
Influ
enza-Related Complications               # Subjec
ts (%)  
Site 
1 Site 
2 Total  Influ
enza 
Type  
Arm 1
 
(n= )  Arm 2
 
(n= )  Total
 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total
 
(n= )  Arm 1
 
(n= )  Arm 2
 
(n= )  Total
 
(n= )  A 
(n= )  B 
(n= )  
Pneum
onia                
Myocardi
al Infarction                 
Strok
e                
Sever
ity of Disease             
 Inten
sive Care Unit (ICU) Admission             
 Mechanical
 Ventilation             
 Oxyge
n Supplementation             
Ordin
al Scale (up to 14 Days)             
 Death   
          
 Mechanical
 Ventilation or 
 Extracorporeal Membrane 
 Oxygenation (ECMO)             
 ICU w
ithout Mechanical 
 Ventilation or ECMO             
 Non-ICU 
Hospi[INVESTIGATOR_059], Requiring 
 Supplemental Oxygen             
 Non-ICU 
Hospi[INVESTIGATOR_059], Not 
 Requiring Supplemental Oxygen             
 Not Ho
spi[INVESTIGATOR_057], but Unable to 
 Resume Normal Activities            
 Not Ho
spi[INVESTIGATOR_057], with Full 
 Resumption of Normal Activities             
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
21 
 Table 7 . Characteristics of Subjects  Initially Admitted to the Hospi[INVESTIGATOR_52096]  # Subjec
ts (%)  
Site 
1 Site 
2 Total  Influ
enza Type  
Arm 1
 
(n= )  Arm 2
 
(n= )  Total
 
(n= )  Arm 1
 
(n= ) Arm 2
 
(n= ) Total
 
(n= ) Arm 1
 
(n= ) Arm 2
 
(n= ) Total
 
(n= ) A 
(n= ) B 
(n= ) 
Sever
ity of Disease             
 Inten
sive Care Unit (ICU) 
Admission             
 Mechanical
 Ventilation             
 Oxyge
n Supplementation             
Ordin
al Scale (up to 14 Days)             
 Death             
 Mechanical
 Ventilation or 
 Extracorporeal Membrane 
 Oxygenation (ECMO)             
 ICU w
ithout Mechanical 
 Ventilation or ECMO             
 Non-ICU 
Hospi[INVESTIGATOR_059], 
Requiring Supplemental Oxygen             
 Non-ICU 
Hospi[INVESTIGATOR_059], 
Not Requiring Supplemental 
Oxygen             
 Not Ho
spi[INVESTIGATOR_057], but 
Unable to Resume Normal 
Activities            
 Not Ho
spi[INVESTIGATOR_057], with Full 
Resumption of Normal Activities             
 
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
22 
 Table 8. Patient Screening and Testing for Influenza  
 
 Site 
1 Site 
2 Total  
N % N % N % 
Patie
nts through ED       
Of Patien
ts through ED, N(%) Screened with 
CDG        
Of Pati
ents Screened with CDG , N(%) Who 
Met Testing Criteria (score ≥3)       
Of Pati
ents Who M et Testing Criteria, N(%) 
Who H ad Tests Ordered        
Of Pati
ents Who M et Testing Criteria, N(%) 
Who H ad Tests Collected and Resulted        
Of Tho
se Tested, N(%) Positive for I nfluenza        
Of T hose 
Tested  Positive , N(%)  Enrolled and 
Randomized        
 
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
23 
 Table 9 . Summary of Adverse Events by [CONTACT_39960], with number (%) of  subjects reporting at least one 
adverse event  
 
SYSTEM 
ORGAN CLAS
S Study
 Arm 1  Study
 Arm 2  Total  
Grade
 of AE  Grade
 of AE  Grade
 of AE  
     Prefe
rred Term  1 2 3 4 5 Total  1 2 3 4 5 Total  1 2 3 4 5 Total  
                       
                       
                       
 
 
 
Table 1
0. Summary of Adverse Events by [CONTACT_52155] 1  Study
 Arm 2  Total  
# Events  % # Events  % # Events  % 
Total N
umber of Adverse Events   -  -  - 
Relat
edness to Study            
 Not r
elated            
 Relat
ed           
Sever
ity of AE            
 Mild            
 Moder
ate           
 Sever
e           
 Poten
tially Life Threatening or 
 D isabling        
 Death   
     
 
 
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
24 
 Table 11 . Frequency of Protocol -Specific Adverse Event  
 
Sympt
oms AE Code  
(Med DRA, 
CTCAE) N (%)  
Aller
gy/Hypersensitivity Reaction      
Rash 
or Skin Reaction      
Alter
ed Mental Status      
---     
     
 
 
  
4.2 Mock Graphs  
Fi
gure 1. Study Patient Screening and Enrollment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
EXCLU
DED : 
•Did not meet enrollment criteria (N =)  
EXCLU
DED:  
•Declined (N =)  
•Did not like the idea of participating in 
research (N =) 
•Felt too sick to be in a study (N =)  
 
 
 
 
Conse
nted 
N = 
Appro
ached  
N =  
Enrol
led & Randomized  
N =  
 
 
EXCLU
DED:  
•Screen Failures (N =)  
•Did not want to wait for required labs 
(N =)  
•HIV exclusion criteria (N = )  
•Liver function exclusion criteria  (N=) 
Met En
rollment Criteria  
N =  
Influ
enza Positive Patients  
N =  
 
Treat
ed and Analyzed  
N =  
 
 
EXCLU
DED:  
•Dropped out  (N =)  Not Ap
proached: 
• Research staff missed patient  (N =)  
• Patient left department prior to Flu Pos 
result (N=)  
• Patient ineligible (N=)  
• Age <18 years  (N=) 
 
SAP       Versi
on 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
26 
  
 
Figure 2. FLU -PRO Symptom Severity Score for Enrolled Patients, by [CONTACT_52142], up 
to 14 Days from Enrollment  
 
Figure 3. Karnofsky Performance Scale, Mean and 95% Confidence Band of Daily Scores  
 
 
Figure 4. Severity of Disease for Hospi[INVESTIGATOR_34297], up t o 14 Days from Enrollment  
 
Figure 5. Ordinal Scale for Hospi[INVESTIGATOR_34297], up to 14 Days from Enrollment  
 
 
 
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
27 
 4.3 Mock Listings  
Listing 1. Patient Level Adverse Events  
 
Patie
nt 
Ident
ifier Site Study
 
Arm Start
 
Date  Resol
utio
n Date  AE Cod
e 
(Med DRA
, CTCA
E) Sever
ity SAE? 
(Y/N)  Relat
ed-
ness Hospi
[INVESTIGATOR_36397]-
zatio
n 
Type  Outco
me Comme
nts 
            
            
            
            
 
Sever
ity of AE:   Relatedness to Study Drug:  
1 = Mil
d  0 = Not related  
2 = Moderate   1 = Related  
3 = Severe    
4 = Potentially Life threatening or disabling   
5 = Death    
Outcome:   Hospi[INVESTIGATOR_059]:  
1 = Ong
oing  0 = None  
2 = Resolved without sequelae   1 = ICU  
3 = Resolved with sequelae   2 = Step down unit 
4 = Death**   3 = Other  
5 = Worsened  
6 = Chronic  
7 = Lost to follow -up 
     
**Provide further details regarding all reported serious AEs and deaths in the SAE and Subject  Deaths tables listed at the end of this  
section.  
 
  
SAP       Versio
n 2.0 
Influenza  Therapeutic Pi[INVESTIGATOR_2268]         5/18/2017  
28 
 Listing 2. Serious Adverse Events  
 
Patie
nt 
Ident
ifier  
Site  
Study
 
Arm  SAE 
Onset
 
Date  Outco
me 
Date  Outco
me SAE 
Class
ification   
Sever
ity Relat
ed to 
Study
 Drug  Descr
iption of Actions 
and O
utcomes (e.g. 
hospi[INVESTIGATOR_52097], 
withd
rawn from study)  
          
          
          
 
Sever
ity of SAE:    Relatedness to Intervention:  
1 = Mil
d   0 = Not related  
2 = Moderate    1 = Related  
3 = Severe    
4 = Life threatening or disabling   
5 = Death    
SAE Classification:      Outcome:  
1 = Dea
th   1 = Ongoing  
2 = Life threatening    2 = Resolved without sequelae  
3 = Inpatient hospi[INVESTIGATOR_059]    3 = Resolved with sequelae  
or prolonged hospi[INVESTIGATOR_059]    4 = Death**  
4 = Persistent/significant disability/incapacity  5 = Worsened  
5 = Resulted in congenital anomaly/birth defect  6 = Chronic  
6 = Important medical event    7 = Lost to follow -up 
 
Listing 3 . Deaths  
Patie
nt 
Ident
ifier  
Site Study
 
Arm  Age Date 
Enrolle
d Treat
me
nt Dat
e Cause
 of 
Death  Date 
of 
Death  Comment
s 
         
         
 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55111] of Abbreviations ................................................................................................................................... 6  
Protocol Summary  ...................................................................................................................................... 8  
Schematic of Study Design  .....................................................................................................................  10 
1. Background  ....................................................................................................................................... 11 
1.1. Scientific Rationale  ...................................................................................................................  11 
1.2. Potential Risks and Benefits ................................................................................................... 11 
1.2.1.  Potential Risks  ......................................................................................................................  12 
1.2.2.  Potential Benefits ..................................................................................................................  14 
2. Objectives  .......................................................................................................................................... 14 
2.1. Study Objectives .......................................................................................................................  14 
2.2. Study Outcome Measures  ...................................................................................................... 15 
3. Systematic Influenza Testing in the Emergency Department  ...................................................  16 
3.1. Clinical Decision Guideline/Electronic Decision Support System Implementation  ........ 16 
3.1.1.  Clinical Decision Guideline  ................................................................................................ . 16 
3.1.2.  Electronic Decision Support System  .................................................................................  17 
3.1.3.  Run-In Period  ........................................................................................................................  18 
3.2. Biological Specimens  ............................................................................................................... 18 
3.2.1. Safety Precautions  ............................................................................................................... 18 
3.2.2.  Sample Collection  ................................................................................................................  18 
3.2.3.  Sample Processing and Labeling  ......................................................................................  18 
3.2.4.  Clinical Use of Waste Specimens  ......................................................................................  19 
4. Screening, Enrollment, and Follow-Up of Study Subjects  .........................................................  19 
4.1. Retrospective Chart Review  ................................................................................................... 19 
4.1.1.  Screening  ...............................................................................................................................  19 
4.1.2.  Eligibility Criteria  ...................................................................................................................  19 
4.1.3.  Informed Consent  .................................................................................................................  20 
4.1.4.  Data Collection .....................................................................................................................  20 
4.2. Methods: Randomized Controlled Trial of Influenza Antivirals  ......................................... 20 
4.2.1.  Eligibility Criteria  ...................................................................................................................  20 
4.2.2.  Screening  ...............................................................................................................................  22 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
3 
 4.2.3.  Informed Consent  .................................................................................................................  23 
5. Study Visit Evaluations: Randomized Controlled Trial of Influenza Antivirals  ........................  23 
5.1. Screening/Enrollment  .............................................................................................................. [ADDRESS_55112] “Check-In”  .................................................................................  [ADDRESS_55113] Compliance to Study Drug  .................................................................... 29 
7. Adverse Event Management  .......................................................................................................... 29 
7.1. General Management of Adverse Events  ............................................................................ 30 
7.2. Protocol-Specific Adverse Event Management  ................................................................... 30 
7.2.1
. Allergy/Hypersensitivity Reaction to Study Drug  .............................................................  30 
7.2.2.  Rash or Skin Reaction  ......................................................................................................... 31 
7.2.3.  Altered Mental Status  .......................................................................................................... 31 
8. Safety Reporting  ...............................................................................................................................  31 
8.1. Documenting, Recording, and Reporting Adverse Events  ................................................  31 
8.1.1.  Adverse Event  .......................................................................................................................  31 
8.1.2.  Serious Adverse Event  ........................................................................................................ 32 
9. Statistical Considerations  ................................................................................................................  33 
9.1. Study Objectives  .......................................................................................................................  33 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
4 
 9.2. Sample Size Considerations  .................................................................................................. 34 
9.3. Final Analysis Plan  ...................................................................................................................  34 
10. Clinical Management Issues  ....................................................................................................... 34 
10.1.  Early Discontinuation of Study Treatment  ........................................................................ 34 
10.2.  Study Withdrawal ..................................................................................................................  35 
11. Protection of Human Subjects & Other Ethical Considerations  ............................................ [ADDRESS_55114]  .................................................................................................. 35 
11.3.  Informed Consent of Study Subjects  .................................................................................  35 
11.4.  Confidentiality of Study Subjects  .......................................................................................  35 
12. Data Management  ........................................................................................................................  36 
12.1.  Data Management Responsibilities  ...................................................................................  36 
12.2.  Data Capture Methods  ........................................................................................................ 37 
12.3.  Data Submission  ..................................................................................................................  37 
12.4.  Quality Control  ......................................................................................................................  37 
12.5.  Protocol Deviations  .............................................................................................................. 38 
12.6.  Source Documents and Access to Source Data/Documents  ........................................ 39 
12.7.  Clinical Site Monitoring  ........................................................................................................ 39 
Appendix 1: Schedule of Evaluations .................................................................................................... 40 
Appendix 2: Shippi[INVESTIGATOR_52098]...................................................  42 
Appendix 2a: Notice of Shipment  .......................................................................................................... 43 
 
  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
5 
 Sponsor and Principal Investigator [INVESTIGATOR_52099] : 
 
 
 
 
 
 
Johns Hopkins University Representative  
 
 
 
 
  Date  
Principal Investigator [INVESTIGATOR_52100] : 
 
I have read and understand this protocol, agree to participate as a Principal  Investigator, will 
ensure the protocol is followed as outlined, and will comply with applicable regulations and with 
Good Clinical Practice.  
 
 
 
 
 
 
Principal Investigator  
 
 
 
 
  [INVESTIGATOR_52101] 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55115] of Abbreviations  
 
AE Adverse Event/Adverse Experience  
AIDS  Acquired Immunodeficiency Syndrome  
ASPR  Assistant Secretary for Preparedness and Response  
BARDA  Biomedical Advanced Research and Development Authority  
BMI Body Mass Index  
CBC  Complete Blood Count  
CDC  Centers for Disease Control and Prevention  
CDG  Clinical Decision Guideline  
CFR Code of Federal Regulations  
Co-PI [CONTACT_15957]-Principal Investigator  
[INVESTIGATOR_52102]  
G6PD  Glucose -6-Phosphate Dehydrogenase  
GCP  Good Clinical Practice  
HAART  Highly Active Antiretroviral Therapy  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
IATA  International Air Transport Association  
ICF Informed Consent Form  
ICU Intensive Care Unit  
ID Identification  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
IT Information Technology  
IV Intravenous  
JHH Johns Hopkins Hospi[INVESTIGATOR_52103] 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55116] Randomized Controlled Trial  
RDC  Remote Data Capture  
SAE Serious Adverse Event/Serious Adverse Experience  
SMC  Safety Monitoring Committee  
SOP  Standard Operating Procedure  
TAT Turnaround  Time  
US [LOCATION_002]  
  
 
  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
8 
 Protocol Summary 
 
Title:  A Pi[INVESTIGATOR_52104]:  Adults  presenting to the emergency department  (ED) with 
laboratory -confirmed influenza who meet Centers for Disease 
Control and Prevention  (CDC ) criteria for antiviral treatment  
Informed Consent : Written informed consent  
Number of Sites:  2 – large, urban, academically -affiliated , US EDs  
Study Duration:  September 2015 – September [ADDRESS_55117] Participation 
Duration:  4 weeks  
Description of Agent 
or Intervention:  Subjects will be randomized to either  oral (oseltamivir ) or 
intravenous ( IV) (peramivir ) antiviral treatment.  
Objective s: 
 This pi[INVESTIGATOR_52105] a primary site for subject enrollment in clinical trials 
evaluating influenza therapeutics,  providing pi[INVESTIGATOR_52086].  
Primary Objective: To prospectively enroll  high-risk subjects with 
laboratory -confirmed influenza into a randomized, open -label study 
of oral versus IV influenza therapeutic to include symptom 
evaluation and outcome assessments . 
Secondary Objective  1: To identify influenza -positive patients 
utilizing a previously established triage -based assessment and rapid 
testing algorithm for suspected influenza infection .  
Secondary Objective 2: To retrospectively evaluate all potentially 
eligible patients for potential enrollment biases . 
Secondary Objective 3 : To create a repository of residual 
nasopharyngeal (NP) samples collect ed from ED patients with  
suspected influenza  illness.  
Description of Study 
Design:  This is a n open -label  randomized  controlled clinical trial in which 
subjects with influenza are randomized to either oral (oseltamivir ) or 
IV (peramivir) antiviral treatment.   
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
9 
 Estimated Time to 
Complete 
Enrollment:  Subject enrollment will occur over  two influenza seasons  (November 
2015 – April 2017 ) or longer, at the co-principal investigators’ (Co -
PIs’) discretion , based on influenza prevalence . 
 
   
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
10 
 Schematic of Study Design  
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  YES Eligibility Criteria (must meet all):  
 18 years of age and older  
 Positive influenza test  
 Meets CDC criteria for antiviral treatment  
 Symptomatic ≤4 days (96 hours) prior to antiviral treatment  
 Able to provide informed consent and comply with follow -up  
 Does not meet any exclusion criteria (see section 4.2.1)  
 
Enrollment and Randomization  
(regardless of severity or disposition 
decision)   Baseline laboratory tests and 
chest x -ray 
 Structured questionnaire 
(demographics, history of 
present illness, past medical 
history)  
Daily Diary (14 days)  
 NO 
Ineligible  
PERAMIVIR (IV)  OSELTAMIVIR (oral)  
Follow -Up (28 days)  
  Symptoms  
 Medication adherence (if applicable)  
 Functional assessment  
 
 Symptoms  
 Other medical visits  
 Functional assessment  
 Chart review (Day 7 and Day 28)  
 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55118] recruited otherwise healthy subjects at clinical sites with 
relatively low rates of recruitment, resulting in the need to engage up to hundreds of recruitment 
sites, and a relative lack of patients with more severe and/or complicated illness. This has 
introduced management challenges with trial implementation and evaluation, including hig h 
associated costs for subject recruitment and retention. 
As the first line of care for many patients with influenza, and over 130 million visits/year, US 
emergency departments (EDs) represent an as yet untapped clinical venue for recruiting 
individuals with influenza into clinical trials. Notably, EDs also have the advantage of caring for 
patients early in their clinical course, and frequently serve as the initial site of care for those with 
complicated and/or severe influenza. Taken together, this creates opportunities which could be 
leveraged for design and implementation of more streamlined influenza therapeutic clinical trial 
design. We propose a pi[INVESTIGATOR_52106], providing data to inform 
future clinical trial design and planning. 
1.2. Potential Risks and Benefits  
The risks and benefits for subjects enrolled in this trial are appropriately balanced. All of the 
study interventions are consistent with recommended clinical practice. The triage algorithm for 
influenza testing is a standard operating procedure (SOP) in the ED from November through 
April. The drugs under study (i.e., oseltamivir and peramivir) have both been approved by [CONTACT_43657] (FDA) for the treatment of acute uncomplicated influenza in 
patients [ADDRESS_55119] been symptomatic for no more than two days. 
Additionally, the Centers for Disease Control and Prevention ( CDC) , Infectious Diseases 
Society of America, and the World Health Organization recommend antiviral treatment with a 
neuraminidase inhibitor as soon as possible for all persons with suspected or confirmed 
influenza who are at higher risk for influenza complications, or who have severe or complicated 
illness . These recommendations come from multiple observational studies showing reduction in 
morbidity and mortality. The strongest evidence remains in hospi[INVESTIGATOR_9643], where both 
early initiation of antiviral treatment (less than two days from illness onset) and treatment up to 
five days after symptom onset were associated with reduced mortality, with greater benefit 
associated with earlier initiation of treatment. All subjects in this study will be adults at higher 
risk for influenza , who are recommended to receive antiviral treatment in accordance with CDC 
recommendations. Many of these subjects may require hospi[INVESTIGATOR_52107]/or underlying conditions. [ http://www.cdc.gov/flu/professionals/antivirals/antiviral-use-
influenza.htm ]  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55120] care. These risks include minor risks associated with study 
participation and adverse events (AEs), including reactions to the study drugs (see below). 
Subjects will be carefully screened to ensure that they meet all study inclusion criteria and do 
not have any exclusion criteria that would put them at unnecessary risk from study participation. 
Subjects will be contact[CONTACT_51095]-up at Day 28, and will have access [ADDRESS_55121]’s underlying medical conditions. To minimize these risks and discomforts, trained 
personnel who have completed all Health Insurance Portability and Accountability Act  (HIPAA) 
training and procedures associated with enrollment of human subjects and study related 
procedures, will approach, consent, enroll patients, and collect data. Further, trained personnel 
will only approach patients and conduct study related activities during patients’ ED wait times, 
decreasing risk of potential increased ED care time associated with study related procedures. 
Baseline laboratory tests and a chest x-ray are non-invasive and standard treatment in the ED, 
and therefore, pose no additional study-associated risk. To minimize any potential discomfort, 
trained personnel will collect all specimens. 
Subjects will be carefully screened for possible AEs after receiving study drug , and will be 
provided with information to contact [CONTACT_52156]. Subjects with findings suggestive of possible AEs will have the appropriate 
investigations performed. Serious adverse events ( SAEs ) will be defined a priori , and reported 
to the independent safety monitor (ISM) and the Institutional Review Board (IRB) as described 
in section 8 ; subjects will be advised and provided with referral sites to seek medical treatment.  
The study will be conducted in accordance with Good Clinical Practice (GCP), and full 
compliance with 21 Code of Federal Regulations (CFR) Parts 11, 50, 54, 56, and 312; 45 CFR 
Part 46 (Protection of Human Subjects); and the HIPAA Privacy Rule. Procedures for managing 
protected health information ( PHI) will be included in the written informed consent form (ICF) . 
Numerous safeguards will be put in place to ensure the confidentiality and integrity of all data, 
addressing both the human and physical elements of protecting subject confidentiality. These 
include data management staff training in protection of human subjects and the ethical conduct 
of human research, systematic backup for the centralized database, use of encrypted data on 
durable media, and utilization of encryption and role-based access mechanisms for remote 
access in compliance with industry best practices and consistent with security and privacy 
requirements of the IRB. Any paper documentation containing PHI, such as informed consen t 
documents, will be stored securely by [CONTACT_3647]. See section 11.[ADDRESS_55122] may receive oseltamivir or peramivir . According to 
the current package insert, the following warnings and precautions, drug interactions, and AEs 
are reported with these study drugs: 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
13 
 Oseltamivir (Tamiflu) 
Warnings and Precautions: 
Serious skin/hypersensitivity reactions such as Stevens-Johnson Syndrome, toxic 
epi[INVESTIGATOR_52108]: Discontinue TAMIFLU and initiate 
appropriate treatment if allergic-like reactions occur or are suspected. 
Neuropsychiatric events: Patients with influenza, including those receiving TAMIFLU, 
particularly pediatric patients, may be at an increased risk of confusion or abnormal 
behavior early in their illness. Monitor for signs of abnormal behavior. 
Drug Interactions: 
Live attenuated influenza vaccine (LAIV), intranasal:  
Do not administer until 48 hours following cessation of TAMIFLU.  
Do not administer TAMIFLU until two weeks following administration of the LAIV , 
unless medically indicated. 
Adverse Reactions: 
Most common adverse reactions (>1% and more common than with placebo): 
Treatment studies – Nausea, vomiting, bronchitis, insomnia, vertigo. 
Prophylaxis studies – Nausea, vomiting, diarrhea, abdominal pain. 
Peramivir (Rapi[INVESTIGATOR_52109]) 
Warnings and Precautions: 
Serious skin/hypersensitivity reactions such as Stevens-Johnson Syndrome and 
erythema multiforme have occurred with RAPI[INVESTIGATOR_52110]. 
Neuropsychiatric events: Patients with influenza may be at an increased risk of 
hallucinations, delirium, and abnormal behavior early in their illness. Monitor for signs of 
abnormal behavior. 
Drug Interactions: 
LAIV, intranasal: Avoid use of LAIV within 2 weeks before or 48 hours after 
administration of RAPI[INVESTIGATOR_52110], unless medically indicated. 
Adverse Reactions: 
Most common adverse reaction (incidence >2%) is diarrhea. 
This study is only enrolling subjects with confirmed influenza who are recommended to receive 
antiviral treatment according to current CDC guidelines, and treating them with appropriate 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55123] shown that oseltamivir reduces mortality, hospi[INVESTIGATOR_7947], and influenza-related complications in various high-risk groups. Peramivir, which is in the 
same neuraminidase inhibitor class as oseltamivir but is delivered in an intravenous (IV) 
formulation, has likewise been approved by [CONTACT_52157] [ADDRESS_55124] will 
be made available as part of the study procedures to provide real time consultation to clinicians 
caring for subjects participating in the study, which may provide additional benefit to subjects 
participating in the study. Finally, participation in this study will help inform future studies of 
influenza treatment, which could help in developi[INVESTIGATOR_52111].  
 
2. Objectives 
2.1. Study Objectives 
Primary Objective: To prospectively enroll high-risk subjects with laboratory-confirmed influenza 
into a randomized, open-label study of oral versus IV influenza therapeutic to include symptom 
evaluation and outcome assessments. 
Secondary Objective 1: To identify influenza-positive patients utilizing a previously established 
triage-based assessment and rapid testing algorithm for suspected influenza infection.  
Secondary Objective 2: To retrospectively evaluate all potentially eligible patients for potential 
enrollment biases. 
Secondary Objective 3: To create a repository of residual nasopharyngeal (NP) samples 
collected from ED patients with suspected influenza illness.  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
15 
 2.2. Study Outcome Measures 
Primary Objective: To prospectively enroll high-risk subjects with laboratory-confirmed influenza 
into a randomized, open-label study of oral versus IV influenza therapeutic to include symptom 
evaluation and outcome assessments. 
Outcomes : The number of subjects successfully enrolled; the proportion of subjects who 
complete treatment with IV or oral study drug in the ED; the proportion of subjects who 
complete follow- up.  
In addition, the following clinical measures will be evaluated for planning future clinical trial 
endpoints: 
 For all subjects: 
o Reported symptoms (including FLU-PRO Symptom Questionnaire); 
o Daily functional assessment; 
o Patient Global Impression of Change (PGIC) on Day 7 and Day 28; 
o Patient Global Impression of Severity (PGIS) at enrollment, and on Day 7 and Day 
28; 
o Number of subsequent medical visits or hospi[INVESTIGATOR_52090] 28 days of enrollment ; 
and 
o Influenza-related complications including pneumonia, myocardial infarction, and 
stroke. 
 For subjects initially admitted to the hospi[INVESTIGATOR_52084]: 
o Severity of disease based on Intensive Care Unit (ICU) admission, mechanical 
ventilation, or oxygen supplementation ; and  
o Ordinal scale up to 14 days: 
 Death; 
 Receiving mechanical ventilation or extracorporeal membrane oxygenation 
(ECMO); 
 In ICU (without mechanical ventilation or ECMO); 
 Non-ICU hospi[INVESTIGATOR_059], requiring supplemental oxygen; 
 Non-ICU hospi[INVESTIGATOR_059], not requiring supplemental oxygen; 
 Not hospi[INVESTIGATOR_057], but unable to resume normal activities; and  
 Not hospi[INVESTIGATOR_52091]. 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
16 
 Secondary Objective 1: To identify influenza-positive patients utilizing a previously established 
triage-based assessment and rapid testing algorithm for suspected influenza infection.  
Outcomes : The proportion of ED patients who were screened for influenza; the proportion of 
screened patients who met testing criteria; the proportion of patients who met testing criteria 
who were tested for influenza; the proportion of patients tested for influenza who were 
positive for influenza. 
Secondary Objective 2: To retrospectively evaluate all potentially eligible patients for potential 
enrollment biases.  
Outcome : The proportion of eligible patients who were enrolled; comparison of demographic 
characteristics between those who were prospectively enrolled versus not enrolled. 
Secondary Objective 3: To create a repository of residual NP samples collected from ED 
patients with suspected influenza illness.  
Outcome : The creation of a robust repository using all remnant samples of patients tested 
using the triage-based assessment and testing algorithm from November 2015 through April 
2017.  
 
3. Systematic Influenza Testing in the Emergency Department 
3.1. Clinical Decision G uideline /Electronic Decision Support System 
Implementation 
Prior to the initiation of the study, a previously derived Clinical Decision Guideline (CDG) for 
ordering influenza testing was fully integrated into the site’s electronic medical record (EMR) 
utilizing an Electronic Decision Support System (EDSS) . This EDSS has now been integrated 
into the EMR at the Johns Hopkins Hospi[INVESTIGATOR_307] (JHH) and at the Maricopa Medical Center (MMC) 
to inform clinician practice. This systematic influenza screening and testing program is part of 
the standard ED practice for recognition and management of patients with suspected influenza. 
3.1.1.  Clinical Decision Guideline  
The previously derived and validated CDG  will guide influenza testing in ED patients as follows: 
A patient will be indicated for influenza testing with Xpert Flu if he/she has a symptom score 
of 3 or greater. The symptom score is based on the following:  
 Within the past 7 days, new or worsening cough (2 points) 
 Within the past 7 days, new headache (1 point) 
 Within the past 7 days, new subjective fever (1 point) 
 Documented temperature at triage of 38 C (100.4 F) or greater (1 point) 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
17 
 3.1.2.  Electronic Decision Support System  
Working collaboratively with a locally determined team (e.g., physicians, nursing, and 
information technology (IT ) staff), the clinical pathway using an EDSS  with the CDG has been 
integrated into the clinical flow and EMR to prompt influenza testing at initial triage. The overall 
flow of the EDSS is depi[INVESTIGATOR_6517] 1. The EDSS will begin functioning in October of each 
influenza season. 
 
 
 
Figure 1: EDSS flow for influenza testing 
 
The EDSS will evaluate if the patient should receive influenza testing by [CONTACT_52158]. To determine if the patient is indicated for Xpert Flu testing , a triage nurse 
will be prompted (at triage) to complete the brief series of questions outlined above. If the 
testing is not indicated by [CONTACT_52159] (i.e., a score of less than 3), then there is no further action 
related to this EDSS. If the patient is indicated for influenza testing according to the CDG  (i.e., a 
score of 3 or greater), then the EDSS will automatically generate a prompt stating that the Xpert 
Flu test is indicated for this patient. If the triage nurse orders the Xpert Flu test , an NP swab will 
be performed, and the specimen will be sent to the laboratory for processing. Alternatively, if the 
influenza test is not ordered, the triage nurse will be prompted to enter one of the following 
reasons for not testing: “Patient refused”; “Patient diagnosed with influenza within previous 48 
hours”; or “Other, (insert text).”  
For any patient receiving an Xpert Flu test through the EDSS, the result of the test will be 
recorded in the EMR when complete. Turnaround time (TAT) from placing the order to result 
received in the EMR will be tracked and it is anticipated that the laboratory will achieve TATs of 
less than 120 minutes (based on historical experience) . However, while this is the expectation, if 
it is not met it does not constitute a protocol violation, as the influenza testing is part of routine 
care. 
Providers may choose to treat or not treat patients as is clinically indicated .  

Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
18 
 3.1.3.  Run-In Period 
Beginning in October and running through April 30 of each influenza season or later, at the co-
principal investigators’ (Co-PIs’) discretion, based on influenza prevalence, all ED patients who 
are assessed at triage will be evaluated by [CONTACT_52160]. To evaluate whether or not the CDG and EDSS are being properly 
implemented, there will be a run-in period during October of each influenza season. The 
purpose of this run-in period is to identify and correct any potential problems with 
implementation of the CDG and EDSS. Principal investigators ( PIs) and research staff will 
cl
osely monitor the implementation of the CDG and EDSS through a standardized monitoring 
and continuous quality improvement (CQI) process. 
During the run-in period, research staff will monitor implementation of the CDG and EDSS to 
ensure that registered ED patients are screened, and if they meet testing criteria, ensure that 
the order is placed and the test occurs. Research staff may be on site to act as a resource or to 
troubleshoot if any problems arise.  
Ongoing monitoring will occur throughout the study period (November 1 – April 30 of each 
influenza season, or later, at the Co- PIs’ discretion, based on influenza prevalence ). 
Additionally, the Biomedical Advanced Research and Development Authority ( BARDA ) 
personnel will periodically conduct an independent audit to provide relevant feedback which will 
be informative for guiding future clinical trials. 
3.2. Biological Specimens  
3.2.1.  Safety Precautions 
All safety guidelines of the local safety committee and/or institutional policies for handling 
biological specimens must be followed. Universal precautions guidelines are to be observed. 
3.2.2.  Sample Collection 
From each patient who is indicated for Xpert Flu testing by [CONTACT_52161], an NP 
sample will be collected by [CONTACT_52162], using a flocked 
swab and universal viral transport media, as is standard clinical practice. All staff collecting NP 
swabs must undergo appropriate training as required by [CONTACT_52163]. Once collected, 
specimens will be transported to the hospi[INVESTIGATOR_52112].  
3.2.3.  Sample Processing and Labeling 
Between November 1 and April 30 of each influenza season, following sample collection, one 
aliquot will be removed for immediate rapid testing using Xpert Flu. A sterile pi[INVESTIGATOR_8462], will be used 
to aliquot the remaining specimen into approximately five 0.5 mL aliquots. Each aliquot will be 
placed in a separate microtube and labeled with a Waste Specimen identification number and 
date of collection. These aliquots will be immediately stored in a - 80⁰C freezer until shipment (a 
log sheet will be maintained on the freezer or in another specified area in the laboratory to 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
19 
 indicate waste sample number, collection date/time, storage time). Freezer boxes will be labeled 
with “BARDA ED FLU PI[INVESTIGATOR_52113],” the collection site, and the lowest waste specimen 
identification number included in that freezer box. If samples go outside of range minus - 20⁰C, 
the samples will be considered compromised and the Coordinating Center must be notified 
immediately. 
3.2.4.  Clinical Use of Waste Specimens  
Leftover samples will be batched, shipped to, and stored at the central study laboratory at JHH 
for future analysis (see Appendix 2). These de-identified samples and results will not be 
available for clinical care. 
 
4. Screening, Enrollment, and Follow- Up of Study Subjects 
This section describes the screening, enrollment and follow-up procedures for the:  
1. Retrospective Chart Review; and the 
2. Randomized Controlled Trial of Influenza Antivirals.  
During the 2015-[ADDRESS_55125] met criteria for enrollment , 
all potentially eligible patients will be evaluated via a retrospective chart review. Basic 
demographic characteristics of patients who were not approached for enrollment, and those 
who were approached but not enrolled, will be compared (in a de-identified manner) with those 
who were enrolled into the Randomized Controlled Trial of Influenza Antivirals. 
4.1.1.  Screening 
Research staff will identify subjects by [CONTACT_52164], or later, at PI [INVESTIGATOR_9106], 
based on influenza prevalence, for patients who meet all eligibility criteria. Basic presenting, 
demographic, and eligibility information will be recorded on the Screening and Enrollment Log 
for every patient who is screened for potential enrollment. Patients that do not meet inclusion 
criteria will be excluded from the Retrospective Chart Review; the reason for exclusion will be 
recorded. 
4.1.2.  Eligibility Criteria 
Inclusion Criteria 
Full ED chart review will be performed on individuals who meet the following inclusion criteria at 
the time of the ED visit: 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
20 
 1) 18 years of age or older; 
2) Adult ED visit between November and April of each influenza season, or later, at the Co-
PIs’ discretion, based on influenza prevalence; and 
3) Positive influenza test associated with the ED visit 
Exclusion Criteria 
There are no exclusion criteria. 
4.1.3.  Informed Consent 
Under a HIPAA waiver of consent, research staff will review patient charts to screen and confirm 
enrollment eligibility. This retrospective evaluation utilizes information that is already collected 
for clinical purposes and all data collected for the retrospective chart abstraction will ultimately 
be stripped of personal identifiers (see section 4.1.4) .  
4.1.4.  Data Collection  
For all eligible patients, research staff will review the ED and hospi[INVESTIGATOR_52114] a set of structured clinical data forms to collect the following: basic demographic data; 
symptoms related to the CDG; criteria for CDC antiviral treatment; initial presentation and 
clinical course at the ED, including antiviral treatment, antibiotic treatment, Xpert Flu test or 
other influenza test information; and hospi[INVESTIGATOR_52115].  
In accordance with HIPAA regulations, no subject personal identifiers will be entered into t he 
study database. Personal identifiers such as name [CONTACT_52192] a separate study identification ( ID) sheet for purposes of completing the 
retrospective chart review. This identifying information will be linked to the remainder of the 
subject information only through the study ID number, and will ultimately be stripped of 
identifying information after all necessary data and samples are collected. Personal identifiers 
will be destroyed upon final completion and verification of the study database. 
All study documents will be kept locked in a limited access area. The study ID sheet that links 
the study ID numbers to the subject personal identifiers will be kept under double lock separate 
from all research files, accessible only to research staff. 
4.2. Methods: Randomized Control led Trial of Influenza Antivirals 
4.2.1.  Eligibility Criteria  
Inclusion Criteria 
To be considered eligible, patients must meet the criteria listed below at the time of screening: 
1) 18 years of age or older; 
2) Laboratory-confirmed positive influenza test associated with their current ED visit; 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
21 
 3) Presence of at least 1 of the following symptoms of acute respi[INVESTIGATOR_52116] ≤4 days 
(96 hours) :  
a. New or increased cough; 
b. New or increased shortness of breath;  
c. Change in sputum production (for adults 65 years of age or older ); 
d. Sinus pain; 
e. Nasal congestion; 
f. Rhinorrhea; 
g. Sore throat ;  
h. Subjective fever; or 
i. Documented fever of ≥38 C. 
4) Meets at least one of the CDC criteria for antiviral treatment, defined as: 
a. 65 years of age or older; 
b. Pregnant* or less than two weeks postpartum; 
c. American Indian or Alaska Native; 
d. Morbid obesity (body mass index (BMI) ≥40 ); 
e. Current resident of nursing home or other chronic-care facility; 
f. Diagnosis of chronic pulmonary disease, cardiovascular disease (except 
hypertension alone), renal disease, hepatic disease, hematologic disease, metabolic 
disorders, neurologic and neurodevelopment conditions, or immunosuppression 
(including that caused by [CONTACT_52165] (HIV) 
infection);  
g. Admission to inpatient or an observation unit; or 
h. Clinical diagnosis of pneumonia (by [CONTACT_52166]) 
*For the purpose of this study, pregnancy is an exclusion criterion. 
Exclusion Criteria 
To be considered eligible for enrollment, a patient must not meet any of the criteria listed below 
at the time of screening: 
1) Does not speak or understand English (JHH); or English or Spanish (MMC);  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
22 
 2) Unable or unwilling to provide informed consent; 
3) Previously enrolled in the study during the current influenza season; 
4) Unable to take oral medication; 
5) Unable to comply with all planned study procedures including availability for follow-up 
and willingness to complete study diary and self-assessment; 
6) Use of neuraminidase inhibitors within the past seven days; 
7) Known allergic reaction to neuraminidase inhibitors; 
8) Pregnant or breastfeeding; 
9) End-stage renal disease, defined as :  
a. Currently undergoing dialysis (either hemo or peritoneal); or  
b. Creatinine clearance (CrCl) of <10 mL/min. 
10) End-stage liver disease, as determined by [CONTACT_52167]; 
11) Glucose-6-phosphate dehydrogenase (G6PD) deficiency by [CONTACT_52168]; 
12) Immunodeficiency, defined as: 
a. Solid organ transplant patients receiving immunosuppression; 
b. Hematopoietic stem cell transplant patients within 12 months of transplant or with 
ongoing immunosuppression; 
c. Oncology patients who have had chemotherapy within the past 30 days; 
d. Current treatment with steroids equivalent to 10 mg of prednisone or more per day 
for greater than two weeks; 
e. Rheumatologic patients receiving immunosuppressive therapy; or 
f. HIV patients who meet one of the following criteria: 
i. Have a CD4 cell count of <200 cells/mm3 within the past 3 months;  
ii. Not actively receiving highly active antiretroviral therapy ( HAART ); or  
iii. Have an absolute lymphocyte count <1.0 x 103 cells/μL conducted at the current 
ED visit 
4.2.2.  Screening 
Eligible subjects will be recruited by [CONTACT_52169] 24 hours a day, 7 days a week. 
Screening and enrollment occur at the same visit.  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55126] during their current ED visit. 
If a patient appears to be eligible, the research staff will approach the patient’s ED provider to 
inform them that the patient is potentially eligible. Alternatively, providers may also refer 
potentially eligible patients to research staff. With the provider’s approval, research staff will 
approach the patient, verify that the patient meets eligibility criteria, and determine if he/she 
would like to participate in the study. 
Eligibility information will be recorded for every patient who is approached for potential study 
enrollment using a Screening and Enrollment Log. Patients who do not meet inclusion criteria or 
who meet an exclusion criteri on will be deemed ineligible; the reason for their exclusion will be 
recorded. Screened patients who meet all inclusion and no exclusion criteria, i.e., who are 
eligible, will be approached for informed consent . For those patients who decline participation, 
the given reason for refusal to participate will be recorded. Screened patients who are eligibl e 
and provide written consent to participate in the study, will be randomized to a treatment arm 
and considered as enrolled in the study.  
4.2.3.  Informed Consent  
Consent forms will be IRB-approved and the patient will be given sufficient time to read and 
review the document and discuss it with his/her family member, friend, or legal representative. If 
he/she requires assistance to reach his/her family member, friend, or legal representative, such 
as the use of a telephone, that will be facilitated. After this, he/she will be specifically asked if 
he/she has any questions or concerns, which will be addressed, or would like more time to 
consider his/her participation, which will also be provided. The investigator or research staff will 
explain the research study to the patient and answer any questions that may arise. The patient 
will sign the ICF prior to any procedures being done specifically for the study. The subject may 
withdraw consent at any time throughout the course of the trial. A copy of the signed informed 
consent will be given to the subject for his/her records; another copy will be included in the 
patient’s chart, and the original will be filed in a study bin der. The rights and welfare of the 
subject will be protected by [CONTACT_52170]. The site PI [INVESTIGATOR_52117]. 
 
5. Study Visit Evaluations: Randomized Controlled Trial of Influenza 
Antivirals 
5.1. Screening/Enrollment 
Following written informed consent, the research staff will complete an eligibility checklist and 
assign a study ID number. The following information and evaluations will be performed :  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
24 
 5.1.1.  Chart Review 
Research staff will gather the following information: 
 Basic laboratory studies: 
o Complete blood count (CBC); 
o Complete or basic metabolic panel; and  
o Serum (or urine) beta-hcg (for women of childbearing potential*) . 
 Calculate CrCl using the Cockcroft Gault equation (see Manual of Operating Procedures 
(MOP )); and  
 Baseline chest x-ray. 
*For the purposes of this study, women will be considered of non-childbearing potential if they 
are greater than age [ADDRESS_55127] had no menses in the previous 12 months or if they are 
surgically sterile (e.g., hysterectomy with or without oophorectomy; fallopi[INVESTIGATOR_52118]; 
endometrial ablation). 
In the majority of cases the above mentioned tests will be obtained for clinical purposes (at the 
time of enrollment or within the previous 24 hours). In cases where any of those tests have not 
been obtained, research staff will complete those tests as part of study procedures; results of 
these laboratory and/or imaging results will be given to the treating ED provider to include in 
his/her medical assessment of the patient. Patients with a CrCl <10 mL/min (or on 
hemodialysis) , a positive beta-hcg, or those who did not have the appropriate laboratory studies 
performed, will be ineligible for enrollment and will not be randomized to receive antiviral 
treatment through this study.  
5.1.2.  Clinical Evaluations 
Demographics and clinical data (medical and health history) will be collected using brief 
structured data forms and will include: 
 Basic demographic data; 
 Vaccination history; 
 Co-morbid illness; 
 History of present illness; 
 Baseline PGIS; and the 
 First day of the validated Daily FLU-PRO Symptom Questionnaire  (F10) and the 
Functional Assessment (F12)  form .  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
25 
 5.1.3.  Treatment Assignment Procedures 
All eligible subjects will be randomized to receive one of two treatment groups using a 
computerized randomization system in the ratio of 1:1. Subjects will be randomized to receive 
either oral or IV antiviral treatment. Randomization will be performed by [CONTACT_52171] , laboratory results, and verification of all eligibility criteria have been 
performed (see MOP). 
5.1.4.  Treatment Administration 
Subjects will begin their treatment regimen in the ED as described below: 
Oseltamivir 
Subjects randomized to the oral treatment arm will receive oral oseltamivir. Oseltamivir will 
be dosed based on CrCl results, as described below.  
 
CrCl Result  
 Dosage of Oral 
Oseltamivir  Frequency /Duration  
>60 mL/min  75 mg  Twice daily (every 12 hours) for 5 days  
>30 – 60 mL/min  30 mg  Twice daily (every 12 hours) for 5 days  
>10 – 30 mL/min  30 mg  Once daily  (every 24 hours) for [ADDRESS_55128] dose will be administered in the ED following randomization. The remaining doses 
will be taken on the subsequent four days, whether they are inpatient or outpatient, based 
on the screening CrCl results . If a dose is missed, subjects will be instructed to take the 
missed dose as soon as they remember, unless it is two hours or less before the next 
scheduled dose ; in this case, subjects will be instructed to discard the missed dose, and 
continue to take the next dose at the usual time. Subjects will be instructed not to take two 
doses at a time to make up for a missed dose. 
Peramivir 
Subjects randomized to the IV treatment group will receive IV peramivir. Peramivir will be 
dosed based on CrCl results, as described below.  
CrCl Result  
 Dosage of IV 
Peramivir  Frequency/ Duration  
≥50 mL/min  600 mg  One time  
30 – 49 mL/min  200 mg  One time  
10 – 29 mL/min  100 mg  One time  
  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55129] an IV line, one will be placed by [CONTACT_49885]. If 
the clinical team’s plan is for the subject to be discharged home from the ED, he/she will receive 
no further study drug . If the clinical team’s plan is for the subject to be admitted to the hospi[INVESTIGATOR_307], 
the subject’s influenza treatment after leaving the ED will be up to the discretion of the inpatient 
treating provider. The inpatient treating provider will be informed of the subject’s participation in 
the study and will be provided with the option to continue the use of IV peramivir at the same 
dose (based on CrCl result ) for each subsequent day for up to four days. Treatment will stop 
upon discharge from the hospi[INVESTIGATOR_307]. Should a subject remain in the hospi[INVESTIGATOR_52119], and the subject is symptomatically better, treatment will stop. If the subject remains 
hospi[INVESTIGATOR_52120], the treating provider will have the 
option to continue the use of IV peramivir daily for another five-day course.  
Study treatment, either oral or IV, may be stopped at the discretion of the treating provider 
should the provider believe that it is in the subject’s best medical interest.  
Treating providers of subjects who are admitted to the hospi[INVESTIGATOR_52121] 24 hour s a 
day/[ADDRESS_55130], who will be available to consult 
on 
the use of peramivir and oseltamivir in admitted subjects. 
5.1.5.  Enrollment Completion 
At the completion of all enrollment processes, subjects will be reminded that they need to 
complete a daily diary (to assess daily symptom severity, safety data, study drug adherence, as 
applicable, and provide a functional assessment) for 14 days between 3:00 PM – 11:[ADDRESS_55131]’s visits to other hospi[INVESTIGATOR_600], should there 
be any subsequent medical encounters in the following [ADDRESS_55132] discharge 
procedures .  
5.2. Follow -Up 
After enrollment (Day 1) , subjects will be expected to complete a daily diary each day for 14 
day
s, and complete “check-ins” on Days [ADDRESS_55133] ’s medical records on Day [ADDRESS_55134] of the following 3 sections : 1) FLU-PRO Symptom Questionnaire 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
27 
 (“Symptom Diary”); 2) medication adherence, side effect profile (including skin reactions and 
rash, neuropsychiatric events, nausea, vomiting, and diarrhea) , and hospi[INVESTIGATOR_52122]; and 
3) a functional assessment.  
Research staff will provide subjects with access to the web-based daily diary. The diary may be 
completed either by [CONTACT_52172] a secure web-based system that can be accessed from a 
person
al web-enabled device, such as a laptop, personal computer, or tablet; or by [CONTACT_52173] ( in-person or telephone) with trained research staff who will ask the questions and 
complete the web-based survey on behalf of the subject. If the subject is in the hospi[INVESTIGATOR_307], 
research staff will visit the subject daily to complete the diary.  
Each day following enrollment, the research staff will review the subject ’s previous day’s diary to 
verify whether or not the diary entry was completed. Missed diary entries cannot be made up. If 
a diary entry is missed, the research staff will call to remind the subject to complete the next 
diary entry as well as all remaining entries. Research staff may also offer to continue to contact 
[CONTACT_52174]. If at any point the subject 
reports a skin reaction , rash, confusion, or hallucinations, research staff will immediately call to 
instruct the subject to return to the ED for evaluation (see section 7 .2). 
5.2.2.  Day [ADDRESS_55135] “Check-In” 
Research staff will call all subjects on Days [ADDRESS_55136] is in the hospi[INVESTIGATOR_52123] D ays 3 and/or 7, research staff 
wi
ll visit the subject in person to complete the “check- in,” and collect an NP swab to assess the 
duration and magnitude of virus shedding . If research staff are unable to reach subjects on 
Days 3 and 7, those “check-in” visits will be considered missed visits. Research staff must 
document
 each attempt made to reach the subject in the research record.   
5.2.3.  Day [ADDRESS_55137] by [CONTACT_52175]-Up Assessment (F13)  form, PGIC, and PGIS. Contact [CONTACT_52176] (unless requested otherwise by [CONTACT_423]) with at least one of the 
calls occurring during non-working hours (i.e., evenings or weekends). Subjects may be 
categorized as “unavailable for follow-up” if: 1) there is a minimum of four failed contact 
[CONTACT_14386]; 2) the provided contact [CONTACT_52177]-functional; or 3) t he subject requests no 
further contact [CONTACT_18925]. 
If the subject remains in the hospi[INVESTIGATOR_307], he/she will undergo an in-person interview to complete the 
required evaluations. 
5.2.4.  Medical Record Review 
Research staff will review subjects’ medical records on Day 7 and Day 28. The following records 
will be reviewed: 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
28 
  Day 7: Medical records from the subject’s enrollment ED visit. 
 Day 28: Medical records from subsequent ED visits, outpatient visits, and 
hospi[INVESTIGATOR_52124] 28. If the subject 
reports visits to other medical facilities at the “check-in” visits, the Day [ADDRESS_55138] 
review. 
6. Study Drug Management 
6.1. Study Drug Supply 
Two types of study drug will be used in the Randomized Controlled Trial of Influenza Antivirals . 
Subjects will be randomized to one of the following treatments: 
 Oseltamivir (oral) ; or 
 Peramivir (IV). 
JHH and MMC will purchase oseltamivir. 
BioCryst Pharmaceuticals, Inc. will provide peramivir to JHH for this study. JHH will distribute 
peramivir to MMC with permission from BioCryst Pharmaceuticals, Inc. 
6.2. Study Drug Formulation and Storage 
Oseltamivir (Tamiflu) 
For this study oseltamivir capsules of 30 mg and 75 mg doses will be used. 
 30 mg capsules (30 mg free base equivalent of the phosphate salt): light yellow hard 
gelatin capsules. “ROCHE” is printed in blue ink on the light yellow body and “30 mg” is 
printed in blue ink on the light yellow cap. 
 75 mg capsules (75 mg free base equivalent of the phosphate salt): grey/light yellow 
hard gelatin capsules. “ROCHE” is printed in blue ink on the grey body and “75 mg” is 
printed in blue ink on the light yellow cap. 
Oseltamivir capsules should be stored at 25 C (77F); excursions permitted to 15  to 30C (59 
to 86 F). 
Peramivir (Rapi[INVESTIGATOR_52109]) 
Peramivir injection is a clear, colorless sterile, isotonic solution. Each single-use vial contains 
200 mg per 20 mL (10 mg/mL) of peramivir in a clear glass vial. Peramivir injection is supplied in 
cartons containing three single-use vials.  
Vials of peramivir injection should be stored in original cartons at 20° to 25°C (68° to 
77°F). Excursions are permitted to 15° to 30°C (59° to 86°F).  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55139]’s CrCl result obtained at 
screening. The first dose of oseltamivir will be administered in the ED. The remaining doses will 
be dispensed and given to the subject before being discharged from the ED (see section 5.1.4). 
Peramivir will be prescribed and dispensed based on the subject’s CrCl result obtained at 
screening. Peramivir is prescribed as a onetime dose to be administered in the ED. If the 
subject is admitted to the hospi[INVESTIGATOR_52084], the inpatient treating provider may choose to 
continue administering IV peramivir (see section 5.1.4). Refer to the peramiv ir package insert for 
instructions on preparing peramivir for IV infusion.  
6.4. Study Drug Labeling 
The Pharmacist of Record (PoR) is responsible for ensuring that each container of study drug , 
dispensed to subjects, is labeled in accordance with federal, local, and institutional labeling 
requirements. The label must bear the statement, "Caution: New Drug --Limited by [CONTACT_4496] (or 
[LOCATION_002]) law to investigational use" per 21 CFR 312.6 (a). 
6.5. Study Drug Accountability 
The PoR at each site is responsible for ordering, receiving, storing, and dispensing study drug 
and will be required to maintain study drug accountability records. Study drug supply must be 
stored separately from other clinical drug supplies and/or hospi[INVESTIGATOR_36507]. At study end all unused 
and expi[INVESTIGATOR_52125] ; peramivir will be 
returned to JHH. Subjects will not return unused study drug (see the MOP).  
6.6. Monitoring Subject Compliance to Study Drug 
To assess subject adherence to oseltamivir, research staff will review the subject’s daily diary 
each day. Subjects will report whether or not study drug for the previous day was taken. This 
information will be abstracted and entered on the Medication Form (F24) . 
 
7. Adverse Event Management 
The 21 CFR 312.32 (a) defines an AE (also referred to as an adverse experience) as any 
unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a drug, and does not imply any judgment about causality. 
An AE can arise with any use of the drug (e.g., off-label use, use in combination with another 
drug) and with any route of administration, formulation, or dose, including an overdose. The 
occurrence of an AE may come to the attention of research staff during or after the study 
procedures and interviews. 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55140] be sought prior to study drug 
discontinuation. 
The following requirements for managing AEs during study participation should be followed, 
unless otherwise specified in section 7.2: 
 Grades 1-4 AEs (not related to study drug): 
Subjects may continue taking study drug per the discretion of the site investigator. The 
site investigator will monitor all AEs unrelated to study drug according to best clinical 
practices. Report the event as an AE, following instructions in section 8.1.1. 
 
 Grades 1 and  2 AEs (related to study drug): 
Subjects may continue taking study drug without alteration of the dosage or frequency, 
with the exceptions noted in section 7.[ADDRESS_55141] from study drug. Report the event as an AE, following 
instructions in section 8.1.1. 
 
 Grades 3 and 4 AEs (related to study drug): 
The site investigator will determine whether or not subjects may continue taking study 
drug based on his/her clinical judgment. The site investigator will closely monitor 
subjects according to best clinical practices until the AE resolves or stabilizes. If the site 
investigator deems that the AE warrants temporary or permanent study drug 
discontinuation, this should be communicated to the protocol team as soon as possible 
and preferably, prior to discontinuing the subject from study drug. Report the event as an 
AE, following instructions in section 8.1.1; and as an SAE if criteria are met, following 
instructions in section 8.1.2. 
7.2. Protocol -Specific Adverse Event Management 
7.2.1.  Allergy/Hypersensitivity Reaction to Study Drug 
If an allergic reaction occurs, instruct the subject to hold the next study drug dose and go to the 
ED immediately. 
 Grades 1 and 2: Discontinue study drug immediately. The site investigator will closely 
monitor the subject according to best clinical practices until the AE resolves or stabilizes. 
Report the event as an AE, following instructions in section 8.1.1. 
 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
31 
  Grades 3 and 4: Discontinue study drug immediately. The site investigator will closely 
monitor the subject according to best clinical practices until the AE resolves or stabilizes. 
Report the event as an AE and SAE, following instructions in sections 8.1.[ADDRESS_55142] to hold the next study drug dose and go to 
the ED immediately. Any rash or skin reaction that is assessed to be possibly, probably, or 
definitely related to study drug will be considered an allergy/hypersensitivity reaction to study 
drug.  
 Grades 1 - 4 (not related): Subjects may continue taking study drug per the discretion of 
the site investigator. The site investigator will monitor all AEs unrelated to study drug 
according to best clinical practices. Report the event as an AE, following instructions in 
section 8.1.1. 
 
 Grades 1 and 2 (related): Refer to section 7.2.1 for AE management instructions.  
 
 Grades 3 and 4 (related): Refer to section 7.2.[ADDRESS_55143] (i.e., phone call follow-up for outpatient and in-person 
follow-up for inpatients), information regarding AEs and unanticipated problems will be elicited 
by [CONTACT_52178].    
8.1.1.  Adverse Event 
All AEs including local and systemic reactions not meeting the criteria for an SAE will be 
captured on the Adverse Events (F20) form. All AEs occurring while on study will be 
documented appropriately regardless of relationship.  
Any medical condition that was present at the time that the subject was screened/enrolled will 
be considered a baseline event. It will not be considered an AE. However, if the event worsens 
at any time after study drug administration through completion of the study period (Day 28), the 
event will be reported as an AE. 
All AEs will be graded for severity and a relationship to the study drug will be assigned. 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
32 
 Severity of all AEs will be assessed by a site investigator using the Division of AIDS (DAIDS) 
Table for Grading the Severity of Adult and Pediatric Adverse Events (Version 2.0, November 
2014). The grading scale is as follows: 
Mild (Grade 1): Mild symptoms causing no or minimal interference with usual social and 
functional activities with intervention not indicated 
Moderate (Grade 2): Moderate symptoms causing greater than minimal interference with 
usual social and functional activities with intervention indicated 
Severe (Grade 3): Severe symptoms causing inability to perform usual social and 
functional activities with intervention or hospi[INVESTIGATOR_52126]-Threatening (Grade 4 ): Potentially life-threatening symptoms causing 
inability to perform basic self-care functions with intervention indicated to prevent 
permanent impairment, persistent disability, or death 
Death (Grade 5 ): Events resulting in death 
Relationship to study drug or causality (likelihood that the event is related to the study drug) will 
be assessed for all AEs by [CONTACT_52179]. For the purposes of investigational 
new drug (IND) safety reporting, ‘reasonable possibility’ of relationship means there is evidence 
to suggest a causal relationship between the study drug and the AE. Such evidence includes 
temporal relationship between study drug administration and event, a known or suspected 
response pattern based on similar agents, and the likelihood (or lack thereof) of an alternative 
etiology. If a site investigator assesses an AE to be definitely, probably, or possibly related to 
study drug, the AE will be reported as related. If an AE can be clearly explained by [CONTACT_52180], then the AE will be reported as not related and an 
alternative etiology will be documented.  
Note: Causality assessment is based on available information at the time of the assessment of 
the event. The investigator and/or the ISM may revise the causality assessment as additional 
information becomes available. 
8.1.2.  Serious Adverse Event  
An SAE is an AE that results in one or more of the following outcomes (International Conference 
on Harmonization (ICH) E6): 
 Death during the period of protocol-defined surveillance. 
 Events that are life-threatening (i.e., an immediate threat to life). 
 Events requiring hospi[INVESTIGATOR_318]. 
 Events resulting in a persistent or significant incapacity or substantial disruption of the 
ability to conduct normal life functi ons. 
 Congenital abnormalities/birth defects. 
 Other important medical events that may jeopardize the subject and may require 
intervention to prevent one of the outcomes listed above. 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
33 
 All SAEs will be recorded on the SAE Report Form (F21) , signed by [CONTACT_978] , and followed until 
satisfactory resolution, or until the event is deemed chronic or the subject is stable.  
Many of the subjects enrolled in this study will have significant influenza-related illness, and it is 
expected that approximately 40% of enrolled subjects will be hospi[INVESTIGATOR_52127] . If the subject is hospi[INVESTIGATOR_52128], the event will not be reported as an SAE. However if the subject’s condition worsens 
after study drug administration and requires prolongation of the hospi[INVESTIGATOR_059], the event will be 
reported as an SAE. Subsequent events that result in hospi[INVESTIGATOR_52129] (see MOP) .  
Site PIs will report all deaths and immediately life-threatening events to the IRB within 24 hours 
of awareness. All remaining SAEs will be reported to the IRB within 7 days of awareness , or per 
institutional policy.  
An ISM will be appointed to provide an independent safety review for SAEs immediately after 
they occur. The ISM will be a clinician with relevant expertise who is not otherwise associated 
with the study.  
A Safety Monitoring Committee (SMC), consisting of the IND sponsor, JHH Co-P Is, Johns 
Hopkins University Research Program Manager, BARDA Medical Officer, the ISM, and the 
study biostatistician will review and monitor the safety and compliance data as well as the 
overall study progress on a regular basis. 
Site PIs will report all SAEs to Westat Regulatory Affairs via fax within one business day of the 
site’s awareness of the event. Westat Regulatory Affairs will notify the ISM and copy the SMC 
within one business day of the SAE Report Form  (F21)  receipt . The ISM will assess the 
relationship of the SAE to the study drug and the expectedness of the event to determine the 
reporting status to the FDA. The ISM will return his assessment to Westat and the SMC within 
24 hours. Westat will report the SAE to the FDA per the ISM’s recommendation. SAEs will also 
be reported to BARDA and BioCryst Pharmaceuticals, Inc. (if the subject is in the peramivir arm) 
within the same timeframe as required by [CONTACT_1622]. 
 
9. Statistical Considerations 
9.1. Study Objectives 
Primary Objective: To prospectively enroll high-risk subjects with laboratory-confirmed influenza 
into a randomized, open-label study of oral versus IV influenza therapeutic to include symptom 
evaluation and outcome assessments. 
Secondary Objective 1: To identify influenza-positive patients utilizing a previously established 
triage-based assessment and rapid testing algorithm for suspected influenza infection. 
Secondary Objective 2: To retrospectively evaluate all potentially eligible patients for potential 
enrollment biases. 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
34 
 Secondary Objective 3: To create a repository of residual NP samples collected from ED 
patients with suspected influenza illness. 
9.2. Sample Size Considerations 
The proposed sample size is at least 50 subjects per site, per influenza season. This sample 
size was determined, in collaboration with ASPR/ BARDA , to be adequate for this pi[INVESTIGATOR_52130], and the ability to reliably 
collect useful therapeutic endpoint data from an ED enrollment site. Estimates are based on 
data from the JHH ED 2014-2015 influenza season using the aforementioned testing algorithm, 
where 1604 patients were tested for influenza between November 2014 and April 2015, and 311 
influenza-positive patients were identified. Of those 311 patients, approximately 75% met CDC 
criteria for influenza treatment (i.e., potential enrollment in the study) and 40% were admitted to 
the hospi[INVESTIGATOR_307]. As 2014-[ADDRESS_55144] approximately 25% fewer influenza-positive patients. Based on 
similar previous ED based therapeutic clinical trials conducted at the JHH ED , it is anticipated 
that 56% of eligible patients will agree to participate in the study. Therefore, assuming a routine 
influenza season, there will be an estimated 174 eligible patients, of whom 97 will be enrolled 
(58 discharged, 39 admitted). Based on these estimates, at least 50 (conservatively) and up to 
225 subjects could be enrolled and follow ed for 28 days. 
9.3. Final Analysis Plan 
As this is an exploratory study, data analysis will be principally descriptive. Rates of discreet 
events, as well as mean values for numerical data will be calculated. Statistical comparisons 
between groups (e.g., Secondary Objective 2) will be completed using t-test or chi squared as 
appropriate. This study is designed to be pi[INVESTIGATOR_52131], and the anticipated sample size ( 225 
subjects) is not sufficient for comparison of outcomes between the two treatment groups. 
Hence, potential clinical endpoints will be described using descriptive statistics for the purposes 
of future trial planning, and no statistical comparisons between the oral and PO antiviral arms 
will be made. 
 
10. Clinical Management Issues 
The following clinical management guidelines apply to both treatment groups. 
10.1.  Early Discontinuation of Study Treatment 
Subjects will be discontinued from study drug for any of the following reasons: 
 Completion of protocol-defined study drug administration period; 
 Any allergic reaction to study drug; 
 Site investigator or treating provider clinical decision to discontinue study drug; or 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
35 
  Request by [CONTACT_1130].  
CRFs will be used to capture both the intended total dosage of study treatment as well as the 
dosage actually received. Reasons for early termination of study treatment will be recorded. 
10.2.  Study Withdrawal 
A subject may be withdrawn from the study for the following reasons: 
 Development of relevant exclusion criteria; 
 Subject withdraws consent to participate in the study; or 
 The study is discontinued. 
All subjects should otherwise be followed according to the protocol. Subjects may withdraw from 
the
 study at any time at their request. Even if a subject does not receive all or any of the 
assigned study treatment, or some required data or specimens cannot be collected, every effort 
should be made to follow subjects for clinical outcomes until the end of the 28-day study period. 
 
11. Protection of Human Subjects & Other Ethical Considerations 
11.1.  Ethical Conduct of the Study  
The study will be conducted according to the Declaration of Helsinki in its current version 
(2013); the requirements of 21 CFR Parts 11, 50, 54, 56, and 312; ICH GCP Guidelines; Human 
Subjects Protection and Data Protection Acts; the US Office for Human Research Protections 
(OHRP); and to the local law and regulations, whichever affords greater protection of human 
subjects. 
11.2.  Institu tional Review Board 
Prior to the initiation of the study, the protocol, ICF, and any subject information materials will be 
submitted to and approved by [CONTACT_52181]. Any future amendments to the study 
protocol, consent materials, and subject information materials will be approved before they are 
placed into use.  
11.3.  Informed Consent of Study Subjects 
Informed consent must be obtained as described previously for enrollment into the Randomized 
Controlled Trial of Influenza Antivirals.  
11.4.  Confidentiality of Study Subjects 
In accordance with HIPAA regulations, no subject personal identifiers will be entered into the 
study database. Personal identifiers such as name, contact [CONTACT_31308], and medical record 
number will be collected and recorded on a separate study ID sheet. This identifying information 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55145] by [CONTACT_52182]. This 
confidentiality will be extended to cover testing of biological specimens and genetic tests in 
addition to the clinical information relating to subjects. The clinical study sites will permit access 
to all documents and records that may require inspection by [CONTACT_52183], IRB, or regulatory agency representatives, including but not limited to, medical 
records (e.g., office, clinic or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this study. 
Data obtained in this study will be maintained in a 21 CFR Part 11-compliant, secure encrypted 
remote data capture (RDC) system. Access to the RDC system is limited to approved 
individuals; the PIs and Westat will set the level of access for individuals to the database. 
Information that can be used to identify specific subjects will not be entered in RDC and will only 
be available to the PIs , other research staff directly involved in the study and that interact with 
the subjects, and site monitors. 
 
12. Data Management 
12.1.  Data Management Responsibilities 
The site investigators are responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported. All CRFs and/or source documents should be completed in a 
neat, legible manner to ensure accurate interpretation of data. Blue or black ink is required to 
ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, cross out the original 
entry with a single line, and initial and date the change.  
Research staff will complete a web-based training for entering study data into the Oracle Clinical 
(OC)-RDC database. Westat will provide training on CRF completion before the start of the 
study. Ongoing in-service trainings may be conducted periodically throughout the study, as 
necessary. Verification of training will be documented and maintained in each site’s study 
regulatory binder. Data collection is the responsibility of the research staff at the sites under the 
supervision of the site investigators. During the study, the site investigators must maintain 
complete and accurate documentation for the study. Data analysis will be the responsibility of 
the Johns Hopkins University Protocol Co-PIs, under the direction of the protocol biostatistician. 
Each subject will be assigned a unique study ID number for use on CRFs and in the database. 
Names or any other personal identifiers will not be entered on any CRF or the study database. 
Forms that contain the subjects’ name, date of birth, or contact [CONTACT_52184]-site 
and filed in a secured cabinet. A study ID sheet, the key linking each subject to his/her unique 
study ID number, will be created and kept secured by [CONTACT_52185], accessible only to research staff. 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55146]’s research record. The subject will not be 
contact[CONTACT_52186]. 
12.2.  Data Capture Methods 
Data will be captured using paper CRFs in blue or black ink with all text printed neatly and 
legibly (i.e., do not use cursive writing except when writing a signature), and with all fields 
completed except when left blank as specified by a skip pattern. Once completed, CRFs will be 
promptly entered into a [ADDRESS_55147] 
from any personal computer , laptop, or tablet; or they may complete the daily diary as an 
interview (phone or in-person) with a research staff member, who will enter the data into the 
database for the subject (see MOP). 
12.3.  Data  Submission 
Sites must follow the guidelines for CRF completion and data entry that are specified in the 
MOP. Once the study database is developed and validated, the RDC screens will be available 
for data entry to research staff who have completed protocol training as well as OC-RDC 
training. Research staff at each site will be responsible for ensuring that CRF data are entered 
into RDC, as specified in the MOP.  
12.4.  Quality Control 
Source data is all information in original records and certified copi[INVESTIGATOR_2149], observations, or other activities in a clinical study necessary for the 
reconstruction and evaluation of the study. All CRFs must have corresponding source 
documentation on file at the clinical sites to substantiate all submitted data, unless the CRF 
serves as the source document. For this study, many of the CRFs will be used as source 
documentation. However, it should be noted that additional source documents may be required, 
such as laboratory reports, hospi[INVESTIGATOR_1097], and clinical memoranda, to describe or clarify data 
reported on the CRFs .  
The CRFs that will serve as source documents are listed in the MOP. 
Data Accuracy Check: Data edits through range checks and field inconsistencies will be built 
into the RDC database to enable real time correction of key entries and CRF completion errors. 
In addition, all data that is entered into OC-RDC will be checked against the CRF shortly after 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
38 
 data entry by a different research staff member. For a randomly selected 10% of the subjects, 
all data forms and data entry will be checked by a different research staff member to ensure 
appropriate data collection. Any corrections will be noted, initialed, and resolved by [CONTACT_52187]. Corrected data will be entered into OC-RDC as appropriate. 
Research staff will generate a report of the data accuracy check. 
If it is determined that the original data recorded on a CRF is incorrect, both the hard copy CRF 
and the electronic database must be updated to reflect the change. The procedure for 
performing data updates is as follows:  
 Using blue or black ink, strike a single horizontal line through the incorrect data value on 
the CRF, taking care not to obliterate the original entry. Do not erase or use white out;  
 Record the correct data value adjacent to the original value;  
 Record your initials and the current date next to the updated information;  
 Make the necessary modifications in OC- RDC. 
Data Completion Check: All data entered into OC-RDC  will be evaluated monthly by [CONTACT_52188]. If at the time of the data completion check there are 
CRFs that have not been entered in OC-RDC, Westat will send site research staff a missing 
forms report by [CONTACT_6968]. Site Research staff will have [ADDRESS_55148]’s missed visit or early termination or request an extension during times of high 
enrollment. These timelines for review and resolution of missing data may be shortened if 
necessary prior to an interim analysis and at the end of the study in an effort to receive the 
necessary data prior to the analysis. . 
12.5.  Protocol Deviations  
A protocol deviation is any non-compliance with the study protocol, GCP, or protocol-specific 
MOP requirements. The noncompliance may be either on the part of the subject, the site 
investigator, or other study personnel. As a result of deviations, corrective actions are to be 
developed by [CONTACT_3483]. 
These practices are consistent with ICH E6: 
4.[ADDRESS_55149] be addressed on the Protocol Deviation  (F22)  
form. A completed copy of the Protocol Deviation form  must be maintained in the regulatory f ile 
as well as in the subject's chart.  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55150] safety and/or eligibility will be reported to the local IRB per its guidelines. 
12.6.  Source Documents and Access to Source Data/Documents 
ASPR/BARDA will assist the Co-PIs in creating source documents for the study prior to subject 
enrollment, including source documents to record information on screening (i.e., meeting 
inclusion and exclusion criteria), enrollment (demographics, patient history, pre-existing 
conditions, etc.), laboratory and medical record data, AEs, and all information entered on the 
CRFs.  
The study sites will maintain appropriate medical and research records for this trial, in 
compliance with ICH E6 and regulatory and institutional requirements for the protection of the 
confidentiality of subjects. Each site will permit authorized representatives of BARDA, its 
designees , site monitors, and appropriate regulatory agencies to examine (and when required 
by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance (QA) reviews, 
audits, and evaluation of the study safety and progress. These representatives will be permitted 
access to all source data, which include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and 
office charts, laboratory notes, memoranda, evaluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, copi[INVESTIGATOR_14848], microfiches, photographic negatives, microfilm or 
magnetic media, x-rays, and subject files and records kept at the pharmacy, at the laboratories, 
and at medico-technical departments involved in the clinical trial. 
12.7.  Clinical Site Monitoring  
Site monitors will visit sites to review selected portions of the individual subject records, 
including consent forms, CRFs, and supporting source documentation to ensure protection of 
study subjects, compliance with the protocol, and accuracy and completeness of records. 
Regulatory files, as required, will also be inspected to ensure that regulatory requirements are 
being followed. 
Site monitors will also visit sites’ investigational pharmacies to review the overall study product 
management system, including receipt, storage, disposition and accountability of study agents. 
Regulatory files kept within the pharmacy will also be inspected to ensure that regulatory 
requirements are being followed. 
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /2016 
40 
 Appendix 1: Schedule of Evaluations 
Evaluation/Test  Screening  Enrollment  Day 3  Day 7 Day 14  Day 28  
Obtain informed consent  x      
Demographics  x      
Medical History  x      
Medical Assessment  x      
CBCa x      
Complete or Basic M etabolic Panela, b x      
Beta-hcg (serum or urine) for women of child -
bearing potentiala, c x      
Chest X-Raya  x     
NP swab for storage   x     
NP Swab: duration and magnitude of virus 
sheddingf   x x   
Study Drug Administrationd  x     
Subject Check -Ine   x x   
Medical Chart Review     x  x 
Follow -Up Assessment       x 
PGIS   x  x  x 
PGIC     x  x 
Daily Diaryg (FLU-PRO  Symptom  
Questionnaire  (F10)  and Functional 
Assessment (F12)  form  x     
Obtain authorization for release of health 
information   x     
a If conducted as part of clinical care at enrollment or within the previous [ADDRESS_55151] had no 
menses in the previous 12 months , or if they are surgically sterile (e.g., hysterectomy with or without 
oophorectomy; fallopi[INVESTIGATOR_52118]; endometrial ablation) . 
d First dose of oral oseltamivir will be administered in the ED; the one time dose of IV peramivir will be 
administered in  the ED.  
e Conduct “check -ins” via phone. If the subject is in the hospi[INVESTIGATOR_307], complete the “check -in,” in person in the 
hospi[INVESTIGATOR_307].  
Seasons 3 & 4 Protocol  Version: 2.0 
Influenza Therapeutic Pi[INVESTIGATOR_2268]  9/26 /[ADDRESS_55152] is hospi[INVESTIGATOR_52132] “check -in” visits.  
g The Daily Diary FLU-PRO  Symptom Questionnaire (F10)  and Functional Assessment (F12)  form will be 
completed in the ED. The subject will complete  the daily diary for [ADDRESS_55153] with trained research staff.  Research staff will review subjects’ d aily diaries each day.    
  
 
42 
 Appendix 2: Shippi[INVESTIGATOR_52133]. These de-identified samples and 
results will not be available for clinical care. 
All shipments will be made in accordance with institutional environmental safety regulations 
regarding shipment of hazardous materials. Frozen samples will be shipped by [CONTACT_52189] (IATA) regulations. The 
laboratory is not open on the weekends or holidays; shipments must be received Monday – 
Friday only (excluding holidays).  
  
Shippi[INVESTIGATOR_52134]: 
 ATTN: Michael Forman  
 Johns Hopkins Hospi[INVESTIGATOR_307] 
 [ADDRESS_55154] 
 Pathology B136 
 Baltimore, MD [ZIP_CODE] 
 Phone: ([PHONE_923]  
 Fax: (410) 614- 8087  
 Email: [EMAIL_974] 
 
When shippi[INVESTIGATOR_52135], create a “notice of shipment” (Appendix 2a: Notice of Shipment) 
that includes the sender’s name, phone and fax numbers, the study IDs, the shippi[INVESTIGATOR_52136], ATTN: Michael Forman. Upon receipt of the 
specimens, someone at the receiving laboratory will sign and fax back the notice, indicating 
receipt of shipment and specimens. 
  
 
43 
 Appendix 2a: Notice of Shipment 
 
NOTICE OF SHIPMENT 
BARDA: Influenza Therapeutic Trial Study  
 
Shippi[INVESTIGATOR_52134]:   
ATTN: Michael Forman  
 Johns Hopkins Hospi[INVESTIGATOR_307] 
 [ADDRESS_55155] 
 Pathology B136 
 Baltimore, MD [ZIP_CODE] 
 Phone: 410- 955-2642  
 Fax: [PHONE_924]   
 Email: [EMAIL_974] 
 
Part I: To be completed by [CONTACT_52190] :  
Senders Name:   
 
[CONTACT_52193]:   
 
Senders Fax Number:   
Study IDs of included 
specimens:   
Shippi[INVESTIGATOR_52137] :  
Part II: To be completed by [CONTACT_52191]’s Research Staff upon receipt of shipment and faxed 
back to Sender: 
Name:   
 
[INVESTIGATOR_7496]:   
 
 